FR2947550A1 - New 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives are akt phosphorylation inhibitors useful for the treatment of e.g. gastric cancers, glioblastoma, Pompe disease, malaria, sleep disorder and leishmaniasis - Google Patents

Abstract

2,3-Dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives (I) and their all possible isomeric forms, racemates, enantiomers, diastereoisomers, or addition salts with mineral and organic acids or bases are new. 2,3-Dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives of formula (I) and their all possible isomeric forms, racemates, enantiomers, diastereoisomers, or addition salts with mineral and organic acids or bases are new. R 1> : -L-aryl or -L-heteroaryl group (both optionally substituted by one or more groups of alkoxy, phenoxy, alkylthio, alkyl, or heterocycloalkyl (all optionally substituted by one or more halo or NR1vR1w), halo, OH, CN, nitro, -COOH, cycloalkyl, -COOalk, NR1xR1y-, -CONR1xR1y, NR1xCOR1y-, -NR1xCO2R1z, or -COR1y, where the heterocycloalkyl and heteroaryl optionally contains one or more oxo); L : 1-6C alkyl (optionally substituted by OH), CO or L1a-X; L1a : 1-6C alkyl; X : O or S; R 2> : H or alkyl; R 3> : alkyl optionally substituted by one or more halo; R 4> : H or halo; either R1x : H or alkyl; and R1y : H, cycloalkyl or alkyl (optionally substituted by one or more OH, alkoxy, NR1vR1w or heterocycloalkyl); or NR1xR1y : 3-10 membered cyclic group optionally containing heteroatoms of O, S, NH or N-alkyl and optionally substituted by one or more halo, alkyl, hydroxyl, oxo, alkoxy, NH 2, NH(alk) or N(alk) 2; either R1v : H or alkyl; and R1w : H, cycloalkyl or alkyl (optionally substituted by one or more OH, alkoxy, or heterocycloalkyl); or NR1vR1w : 3-10 membered cyclic group optionally containing heteroatoms of O, S, NH or N-alkyl and optionally substituted by one or more halo, alkyl, hydroxyl, oxo, alkoxy, NH 2, NH(alk) or N(alk) 2; and R1z : cycloalkyl or alkyl (optionally substituted by one or more OH, alkoxy, NR1vR1w or heterocycloalkyl), where all the alkyl (alk), alkoxy and alkylthio are linear or branched 1-6C alkyl, 1-6C alkoxy and 1-6C alkylthio. Independent claims are included for: (1) intermediates comprising 7-hydroxy-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one compound of formula (D), 7-chloro-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one compound of formula (E), 7-morpholin-4-yl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one compound of formula (F) and 7-chloro-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one compound of formula (J); and (2) the preparation of (I). R : alkyl; X : Cl, Br, I, sulfonyloxy or trifluoromethylsulfonyloxy. [Image] [Image] ACTIVITY : Cytostatic; Metabolic; Antiparasitic; Antimalarial; Hypnotic; Protozoacide. MECHANISM OF ACTION : Akt Phosphorylation inhibitor; Protein kinase B (PKB) inhibitor. The ability of (I) to inhibit AKT phosphorylation was tested in human prostate carcinoma cells using western blotting technique. The result showed that (S)-2-methyl-7-morpholin-4-yl-1-((R)-2-phenyl-propyl)-2-trifluoromethyl-2,3-dihydro-1H-imidazo[1,2-a]pyrimidin-5-one exhibited an IC 5 0value of 15 nM.

Description

NOVEL 2,3-DIHYDRO-1H-IMIDAZO {1,2-a} PYRIMIDIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS AKT PHOSPHORYLATION INHIBITORS (PKB) The present invention relates to novel chemical compounds ( 2,3-dihydro-1H-imidazo {1,2-a} pyrimidin-5-one), pyrimidinone derivatives, process for their preparation, the novel intermediates obtained, their use as medicaments, the pharmaceutical compositions containing them and the new use of such derivatives.

The present invention thus also relates to the use of said derivatives for the preparation of a medicament for the treatment of humans. More particularly, the invention relates to novel pyrimidinone derivatives and their pharmaceutical use for the prevention and treatment of conditions capable of being modulated by inhibition of the PI3K / AKT / mTOR pathway. AKT is a key player in this signaling path. A high level of AKT phosphorylation is the marker of pathway activation that is found in many human cancers. The products of the present invention can thus be used in particular for the prevention or treatment of conditions capable of being modulated by the inhibition of AKT phosphorylation (P-AKT). The inhibition of P-AKT can be obtained in particular by the inhibition of the PI3K / AKT / mTOR pathway, and in particular by the inhibition of kinases belonging to this pathway such as receptors with tyrosine kinase activity such as EGFR, IGFR, ErbB2 , 3'-phosphoinositide-dependent protein kinase-1 (PDK1), phosphoinositide kinase PI3K, serine threonine kinase AKT, mTOR kinase. The inhibition and regulation of the PI3K / AKT / mTOR pathway is a novel and powerful mechanism of action for the treatment of a large number of cancerous diseases including solid and fluid tumors. Such conditions which can be treated by the products of the present application are solid or liquid human tumors. Role of the PI3K / AKT / mTOR pathway The PI3K / AKT / mTOR signaling pathway is a complex network that regulates multiple cellular functions, such as growth, survival, proliferation and cell motility, which are key processes in the pathway. tumorigenesis.

This signaling pathway is an important target in the treatment of cancer because most of its effectors are altered in human tumors. The main effectors contributing to the activation of the pathway are: i) oncogenes such as ErbB1 (EGFR), ErbB2 (HER2), PIK3CA and AKT activated by mutation, amplification or overexpression; ii) the deficiency of tumor suppressor genes such as PTEN, TSC1 / 2, LKB and PML that are inactivated by mutations or deletions (Jiang LZ & Liu LZ, Biochim Biophys Acta, 2008, 1784: 150; & Sawyers CL, 2002, Nat Rev Cancer, 2: 489, Cully M et al., Nature Rev. Cancer, 2006, 6: 184). Activation of oncogenes of this signaling pathway is found in many human cancer diseases. PIK3CA activating mutations are present in 15-30% of colon, breast, endometrial, liver, ovarian and prostate cancers (TL Yuan and LC Cantley, Oncogene, 2008, 27: 5497). Y. Samuels et al., Science, 2004, 304: 554, KE Bachman et al.

Cancer Biol Ther, 2004, 3: 772; DA Levine et al. Clin Canc Res. 2005, 11: 2875; C. Hartmann et al. Acta Neuropathol. 2005, 109: 639). amplifications, activating and overexpressing mutations of RTKs such as EGFR and HER2 in brain, breast and lung cancers (NSCLC) - amplification and activating overexpression of AKT in brain, lung and lung cancers (NSCLC) ), breast, kidney, ovary and pancreas (Testa JR and Bellacosa A., Proct Natl Acad Sci USA 2001, 98: 10983, Cheng et al., Proc Natl Acad. Sci USA 1992, 89: 9267, Bellacosa et al., Int J Cancer, 1995, 64: 280, Cheng et al., Proc Natl Acad Sci USA 1996, 93: 3636, Yuan et al. Oncogene, 2000, 19: 2324).

The deficiency of the tumor suppressor genes of this signaling pathway is also found in many human cancer diseases: o the deletion of PTEN in 50% of lung cancers (NSCLC), liver, kidney, prostate, breast , brain, pancreas, endometrium and colon (Maxwell GL et al., Res Res 1998, 58: 2500, Zhou XP et al., J. Pathol., 2002, 161: 439; & Baker SJ, Oncogene, 2008, 27: 5416, Li et al., Science, 1997, 275: 1943, Steack PA et al., Nat Genet., 1997, 15: 356), the mutations of TSC1 / 2 in more 50% of tuberous sclerosis o mutations or deletions of LKB1 (or STK11) which predispose to cancers of the gastrointestinal tract and pancreatic cancer and which are found in particular in 10-38% of lung adenocarcinomas (Shah U. et al., Cancer Res., 2008, 68: 3562), the PML modification by translocation in human tumors (Gurrieri C et al., J. NAtI Cancer Inst. 96: 269). In addition, this signaling pathway is a major factor of resistance to chemotherapy, radiotherapy and targeted therapies such as EGFR and HER2 inhibitors for example (C. Sawyers et al., Nat Rev 2002).

Role of AKT AKT (protein kinase B, PKB) is a serine-threonine kinase that occupies a central place in one of the major cell signaling pathways, the PI3K / AKT pathway. AKT is particularly involved in the growth, proliferation and survival of tumor cells. Activation of AKT is carried out in two steps (i) by phosphorylation of threonine 308 (P-T308) by PDK1 and (2) by phosphorylation of serine 473 (P-S473) by mTORC2 (or mTOR-Rictor complex). ), resulting in total activation. AKT in turn regulates a large number of proteins including mTOR (mammalian target of Rapamycin), BAD, GSK3, p21, p27, FOXO or FKHRL1 (BD Manning & Cantley LC, Cell, 2007 129: 1261). Activation of AKT promotes the internalization of nutrients, which triggers anabolic metabolism process supporting cell growth and proliferation. In particular, AKT controls the initiation of protein synthesis through a cascade of interactions that proceeds via TSC1 / 2 (tuberous sclerosis complex), Rheb, and TOR to achieve two critical targets of the pathway. signaling, p7OS6K and 4EBP. AKT also induces inhibitory phosphorylation of the Forkhead transcription factor and inactivation of GSK3I3 that lead to inhibition of apoptosis and cell cycle progression (Franke TF, Oncogene, 2008, 27: 6473). AKT is therefore a target for anti-cancer therapy and inhibition of AKT activation by inhibition of its phosphorylation can induce apoptosis of malignant cells and thus, present a treatment for cancer. Receptors with tyrosyne kinase activity such as IGF1 R Abnormally high levels of protein kinase activity have been implicated in many diseases resulting from abnormal cell functions. This can come either directly or indirectly, from a dysfunction in the mechanisms of kinase activity control, linked for example to a mutation, an over-expression or an inappropriate activation of the enzyme, or by an over- or under- -production of cytokines or growth factors, also involved in signal transduction upstream or downstream of kinases. In all these cases, a selective inhibition of the kinase action suggests a beneficial effect. The type 1 receptor for insulin-like growth factor (IGF-IR) is a transmembrane receptor with tyrosine kinase activity that binds primarily to IGFI but also to IGFII and insulin with a higher low affinity. The binding of IGF1 to its receptor results in oligomerization of the receptor, activation of tyrosine kinase, intermolecular autophosphorylation and phosphorylation of cellular substrates (major substrates: IRS1 and Shc). The ligand-activated receptor induces mitogenic activity in normal cells. However, IGF-I-R plays an important role in so-called abnormal growth.

Several clinical reports highlight the important role of the IGF-I pathway in the development of human cancers: IGF-IR is often found to be over-expressed in many tumor types (breast, colon, lung, sarcoma, prostate, multiple myeloma) and its presence is often associated with a more aggressive phenotype. High circulating IGF1 concentrations are strongly correlated with a risk of prostate, lung and breast cancer. In addition, it has been widely documented that IGF-I-R is required for the establishment and maintenance of the transformed phenotype in vitro as in vivo [Baserga R, Exp. Cell. Res., 1999, 253, pages 1-6]. The kinase activity of IGF-I-R is essential for the transformation activity of several oncogenes: EGFR, PDGFR, SV40 large-virus antigen, activated Ras, Raf, and v-Src. Expression of IGF-I-R in normal fibroblasts induces a neoplastic phenotype, which can then lead to tumor formation in vivo. The expression of IGF-I-R plays an important role in the independent growth of the substrate. IGF-I-R has also been shown to be a protector in apoptosis induced by chemotherapy, radiation, and cytokine-induced apoptosis. In addition, inhibition of endogenous IGF-IR by a dominant negative, triple helix formation or expression of antisense causes suppression of the transforming activity in vitro and decrease of tumor growth in the cells. animal models. PDK1 3'-Phosphoinositide-dependent protein kinase-1 (PDK1) is one of the essential components of the PI3K-AKT signaling pathway. It is a serine-threonine (Ser / Thr) kinase whose role is to phosphorylate and activate other Ser / Thr kinases of the AGC family involved in the control of growth, proliferation, cell survival and in the regulation of metabolism. These kinases include protein kinase B (PKB or AKT), SGK (or serum and glucocorticoid regulated kinase), RSK (or p90 ribosomal S6 kinase), p7OS6K (or p70 ribosomal S6 kinase), and various isoforms of protein kinase C ( PKC) (Vanhaesebroeck B. & Alessi DR., Biochem J, 2000, 346: 561). One of the key roles of PDK1 is the activation of AKT: in the presence of PIP3, the second PI3K-generated messenger, PDK-1 is recruited to the plasma membrane via its PH domain (plekstrin homology) and phosphorylates AKT on threonine. 308 located in the activation loop, an essential modification of AKT activation. PDK1 is ubiquitously expressed and is a constitutively active kinase. PDK1 is a key element in the PI3K / AKT signaling pathway for the regulation of key processes in tumorigenesis such as cell proliferation and survival. Since this pathway is activated in more than 50% of human cancers, PDK1 represents a target for cancer therapy. Inhibition of PDK1 should result in effective inhibition of cancer cell proliferation and survival and thus provide therapeutic benefit for human cancers (Bayascas JR, Cell Cycle, 2008, 7: 2978, Peifer C. & Alessi DR ChemMedChem, 2008, 3: 1810). Phosphoinositide-3 kinases (PI3Ks) PI3K lipid kinase is an important target in this signaling pathway for oncology. PI3Ks of class I are divided into class la (P13Ka, 13.6) activated by receptors with tyrosine kinase activity (RTKs), G-protein coupled receptors (GPCRs), GTPases of the Rho family, p21-Ras and in class Ib (PI3Ky) activated by the GPCRs and by p21-Ras. PI3Ks of class la are heterodimers which consist of a catalytic subunit p10a, (3 or 6 and a p85 or p55 regulatory subunit, class Ib (p110y) is monomeric, P13Ks of class I are lipids / protein kinases that are activated by RTKs, GPCRs or Ras after membrane recruitment These class I P13Ks phosphorylate phosphatidylinositol 4,5 diphosphate (PIP2) at position 3 of inositol to give phosphatidylinositol 3, 4.5 triphosphate (PIP3), a key secondary messenger of this signaling pathway.In turn, PIP3 recruits AKT and PDK1 to the membrane where they bind to their domain homologous to the pleckstrin (PH domain), leading to activation. AKT by phosphorylation of PDK1 on Threonine 308. AKT phosphorylates many substrates, thus playing a key role in many processes resulting in cell transformation such as proliferation, growth and cell survival as well as than angiogenesis.

Class I PI3Ks are involved in human cancers: Somatic mutations of the PIK3CA gene that codes for PI3Ka are found in 15-35% of human tumors including two main oncogenic mutations H1047R (in the kinase domain) and E545K / E542K ( in the helical domain) (Y. Samuels et al., Science, 2004, 304: 554, TL Yuan and LC Cantley, Oncogene, 2008, 27: 5497). PI3K inhibitors are expected to be effective for the treatment of many human cancers with genetic alterations leading to activation of the P13K / AKT / mTOR pathway (Vogt P. et al., Virology, 2006, 344: 131; Vogt PK, Oncogene, 2008, 27: 5486). Morpholino pyrimidinone derivatives which are kinase inhibitors are known to those skilled in the art. The WO2008 / 148074 application describes products that have mTOR inhibitory activity. These products are pyrido [1,2-a] pyrimidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions. The application WO2008 / 064244 describes the application of the P13K13 inhibitor TGX-221 and TGX-155 products useful in the treatment of cancer, and in particular in breast cancer. These products are pyrido [1,2-alpyrimidin-4-ones previously described in applications WO2004 / 016607 and WO2001 / 053266 which differ from the products of the present invention because of their wholly aromatic character and their substitutions. Applications WO2006 / 109081, WO2006 / 109084 and WO2006 / 126010 disclose DNA-PK inhibitory products useful for the treatment of deficient ATM cancers. These products are pyrido [1,2-a] pyrimidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions. The application WO2003 / 024949 discloses DNA-PK inhibitory products. useful for the treatment of deficient ATM cancers. These products are pyrido [1,2-a] pyrimidin-4-ones which differ from the products of the present invention because of their wholly aromatic character and their substitutions. The subject of the present invention is the products of formula (I): R 3 (R 2 N-R 1 in which: R 1 represents a -L-aryl or -L-heteroaryl radical, such that L represents: either a linear or branched alkyl radical containing from 1 to 6 carbon atoms and optionally substituted with a hydroxyl radical; either a CO group or a group L'-X where L 'represents a linear or branched alkyl radical containing 1 to 6 carbon atoms and X an oxygen or sulfur atom, the aryl and heteroaryl radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, CN, nitro, -OOH, -COOalk, -NRxRy, -CONRxRy, -NRxCORy, -NRxCO2Rz, -CORy, alkoxy, phenoxy, alkylthio radicals; , alkyl, cycloalkyl and heter these alkoxy, phenoxy, alkylthio, alkyl and heterocycloalkyl radicals, themselves being optionally substituted by one or more identical or different radicals chosen from halogen atoms and NRvRw; heterocycloalkyl and heteroaryl radicals additionally capable of containing an oxo radical; R2 represents a hydrogen atom or an alkyl radical; R3 represents an alkyl radical optionally substituted with one or more halogen atoms; R4 represents a hydrogen atom or a halogen atom; NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and NRvRw radicals; and heterocycloalkyl; either Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted; NRvRw being such that Rv represents a hydrogen atom or an alkyl radical and Rw represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and heterocycloalkyl radicals; ; either Rv and Rw form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted; the cyclic radicals that can be formed by Rx and Ry or Rv and Rw respectively with the nitrogen atom to which they are attached, being optionally substituted by one or more identical or different radicals chosen from halogen atoms, alkyl radicals, hydroxyl radicals, oxo, alkoxy, NH2; NHalk and N (alk) 2; Rz represents the values of Ry with the exception of hydrogen; Rx, Ry and Rz in the radicals -NRxCORy, -CORy and NRxCO2Rz being selected from the meanings indicated above for Rx, Ry, and Rz; said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as the addition salts with mineral and organic acids or with the inorganic and organic bases of said products of formula (I). In the products of formula (I): the term "alkyl radical (or alk)" denotes the radicals, linear and, if appropriate, branched, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl; , isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl and their linear or branched positional isomers: alkyl radicals containing from 1 to 6 carbon atoms and more particularly alkyl radicals containing from 1 to 4 atoms are preferred. carbon from the list above; the term "alkoxy radical" denotes the linear and, if appropriate, branched, methoxy, ethoxy, propoxy, isopropoxy, linear butoxy, secondary or tertiary, pentoxy or hexoxy radicals, as well as their linear or branched positional isomers: alkoxy radicals containing 1 to 4 carbon atoms from the above list; the term "alkylthio radical" denotes the linear and, if appropriate, branched, linear, secondary or tertiary methylthio, propylthio, isopropylthio, butylthio, pentylthio or hexylthio radicals, as well as their linear or branched positional isomers: alkylthio radicals containing 1 to 4 carbon atoms from the above list; the term "halogen atom" denotes the chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom. the term "cycloalkyl radical" denotes a saturated carbocyclic radical containing 3 to 10 carbon atoms and thus particularly denotes the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and especially the cyclopropyl, cyclopentyl and cyclohexyl radicals; in the -O-cycloalkyl radical, cycloalkyl is as defined above; the term "heterocycloalkyl radical" thus denotes a monocyclic or bicyclic carbocyclic radical containing from 3 to 10 members interrupted by one or more heteroatoms, which may be identical or different, chosen from oxygen, nitrogen or sulfur atoms; for example morpholinyl, thiomorpholinyl, homomorpholinyl, aziridyl, azetidyl, piperazinyl, piperidyl, homopiperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydrothienyl, tetrahydropyran, oxodihydropyridazinyl or oxetanyl radicals being optionally substituted; mention may in particular be made of morpholinyl, thiomorpholinyl, homomorpholinyl, piperazinyl, piperidyl, homopiperazinyl or pyrrolidinyl radicals, the terms aryl and heteroaryl denote unsaturated or partially unsaturated, respectively carbocyclic and heterocyclic, monocyclic or bicyclic radicals, containing at most 12 links, optionally containing a -C (O) linkage, heterocyclic radicals containing one or more identical or different heteroatoms selected from O, N, or S with N, optionally substituted; the term "aryl radical" thus denotes monocyclic or bicyclic radicals containing 6 to 12 members, such as, for example, the phenyl, naphthyl, biphenyl, indenyl, fluorenyl and anthracenyl radicals, more particularly the phenyl and naphthyl radicals and even more particularly the phenyl radical. It may be noted that a carbocyclic radical containing a C - (O) - linkage is, for example, the tetralone radical; the term "heteroaryl radical" thus denotes monocyclic or bicyclic radicals containing 5 to 12 ring members: monocyclic heteroaryl radicals such as, for example, thienyl radicals such as 2-thienyl and 3-thienyl, furyl such as 2-furyl, 3-furyl, pyrannyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, pyridyl such as 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, isothiazolyl, diazolyl, thiadiazolyl, thiatriazolyl, oxadiazolyl, isoxazolyl as 3- or 4-isoxazolyl, furazannyl, free or salt tetrazolyl, all these radicals being optionally substituted, among which more particularly the thienyl radicals such as 2-thienyl and 3-thienyl, furyl such as 2-furyl, pyrrolyl, pyrrolinyl, pyrazolinyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, pyridazinyl, these radicals being optionally substituted; bicyclic heteroaryl radicals such as, for example, benzothienyl radicals such as 3-benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, dihydroquinolyl, quinolone, tetralone, adamentyl, benzofuryl, isobenzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thianthrenyl, benzopyrrolyl, benzimidazolyl, benzoxazolyl, thionaphthyl, indolyl; azaindolyl, indazolyl, purinyl, thienopyrazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydrofuropyrazolyl, tetrahydropyrrolopyrazolyl, oxotetrahydropyrrolopyrazolyl, tetrahydropyranopyrazolyl, tetrahydropyridinopyrazolyl or oxodihydropyridino pyrazolyl, all of these radicals being optionally substituted; As examples of heteroaryl or bicyclic radicals, there may be mentioned more particularly the pyrimidinyl, pyridyl, pyrrolyl, azaindolyl, indazolyl or pyrazolyl, benzothiazolyl or benzimidazolyl radicals optionally substituted by one or more identical or different substituents as indicated above. The carboxyl group (s) of the products of formula (I) may be salified or esterified with the various groups known to those skilled in the art, among which may be mentioned, for example: - among salification compounds, mineral bases such as, for example, an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine, arginine, histidine, N-methylglucamine among the esterification compounds, the alkyl radicals to form alkoxycarbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals being able to be substituted by radicals chosen from, for example, halogen atoms, hydroxyl, alkoxy, acyl, acyloxy, alkylthio, amino or aryl radicals such as, for example, chloromethyl, hydroxypropyl, methoxymethyl, propionyloxymethyl, methylthiomethyl, dimethylaminoethyl, benzyl groups; or phenethyl. The addition salts with the inorganic or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulphonic acids such as, for example, methanesulfonic acid, ethanesulphonic acid, propanesulphonic acid, alkylsulphonic acids such as, for example, methanedisulfonic acid, alpha, beta-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulphonic acid and aryldisulphonic acids. It may be recalled that the stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but whose different groups are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in axial or equatorial position, and the different possible rotational conformations of the ethane derivatives. However, there is another type of stereoisomerism, due to the different spatial arrangements of fixed substituents, either on double bonds or on rings, often called geometric isomerism or isomeric cistrans. The term stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above. The subject of the present invention is the products of formula (I) as defined above in which: R 1 represents a radical -L-phenyl or -L-heteroaryl, such that L represents: either a linear or branched alkyl radical containing 1 to 6 carbon atoms and optionally substituted by a hydroxyl radical, either a CO group or a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X a hydrogen atom. oxygen or sulfur; the phenyl and heteroaryl radicals being optionally substituted by one or more identical or different radicals chosen from halogen atoms and -NRxRy, alkoxy and alkyl radicals; The latter alkoxy and alkyl radicals themselves being optionally substituted with one or more radicals selected from halogen atoms; R2 represents an alkyl radical; R3 represents an alkyl radical optionally substituted with one or more halogen atoms; R4 represents a hydrogen atom or a fluorine atom; NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom or an alkyl radical; either Rx and Ry form with the nitrogen atom to which they are bonded a morpholino radical; all the above alkyl (alk) or alkoxy radicals being linear or branched and containing from 1 to 6 carbon atoms, said products of formula (I) being in all possible isomeric racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I). In particular, when NRxRy or NRvRw forms a ring as defined above, such an amine ring may be chosen especially from the pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, azepinyl, morpholinyl, homomorpholinyl, piperazinyl or homopiperazinyl radicals, these radicals being themselves optionally substituted as indicated above or hereinafter. The NRxRy or NRvRw ring may more particularly be chosen from pyrrolidinyl, morpholinyl radicals optionally substituted by one or two alkyl or piperazinyl radicals optionally substituted on the second nitrogen atom by an alkyl, phenyl or CH 2 -phenyl radical, themselves same optionally substituted with one or more identical or different radicals selected from halogen atoms and alkyl, hydroxyl and alkoxy radicals.

The subject of the present invention is particularly the products of formula (I) as defined above, corresponding to the following formulas: - (2S) -1- [2- (4-methoxyphenyl) ethyl] -2-methyl-7- (Morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - 1- [2- (4-methoxyphenyl) ethyl) ] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1- benzyl-2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2- methyl-7- (morpholin-4-yl) -1- (2-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S 2-methyl-7- (morpholin-4-yl) -1- (3-phenylpropyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) - one - (2S) -2-methyl-7- (morpholin-4-yl) -1- (2-phenoxyethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 ( 1 H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1- [2- (phenylsulfanyl) ethyl] -2- (trifluoromethyl) -2,3-d ihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2R) -2-phenylpropyl] -2- (Trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) 2-phenylpropyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1 - [(2S) -2-hydroxy-2 phenylethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) ) -1 - [(2R) -2-hydroxy-2-phenylethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] ] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) -1-phenylpropan-2-yl] -2- (trifluoromethyl) 2,3-Dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(1S) 1-phenylpropyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-) yl) -1 - [(1R) -1-phenylpropyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2- methyl-7- (mor pholin-4-yl) -1- {2- [4- (morpholin-4-yl) phenyl] ethyl} -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimid in-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] ] pyrimidin-5 (1H) -one - 1- [2- (4-methoxyphenyl) ethyl] -2,2-dimethyl-7- (morpholin-4-yl) -2,3-dihydroimidazo [1,2-d] a] pyrimidin-5 (1H) -one as well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I).

The subject of the present invention is in particular the products of formula (I) as defined above, corresponding to the following formulas: - (2S) -6-fluoro-1- [2- (4-methoxyphenyl) ethyl] -2-methyl (Morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1-benzyl- 6-fluoro-2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one, and salts thereof. addition with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I).

The present invention also relates to any process for preparing the products of formula (I) as defined above. The products according to the invention can be prepared from conventional methods of organic chemistry. Preparation of compounds of formula (I) The general scheme 1 below is illustrative of the methods used for the preparation of the products of formula (I). As such, they can not constitute a limitation of the scope of the invention, as regards the methods of preparation of the claimed compounds. The products of formula (I) as defined above according to the present invention can thus be prepared in particular according to the method described in general scheme 1. The subject of the present invention is therefore also the process for the preparation of products of formula (I ) according to the general scheme 1 as defined below.

General Scheme 1: NH HBr HZN BrCN NH, HN) NH ~ R3 Chlorination R3 R2 A R2 DEB R3 Morpholine H R2 E R1-X G Alkylation F R2 R3 (1) J In General Scheme 1: The diamines A are either commercial or prepared in a chiral or racemic version, according to the method described by Brigaud, T. et al. in J.

Org. Chem. 2006, 71 (18), 7075-7078, when R2 = CF3 and R3 = Me or by analogy with this same reference in the other cases. Guanidines B may be obtained by reaction of a diamine A and cyanogen bromide in a solvent such as water or acetonitrile, at a temperature between 0 ° C. and the boiling point of the solvent, depending on the conditions described for example by Gallet, T. et al. (EP1340761 2003). The compounds D can be obtained by condensation of a guanidine B with a dialkyl (preferably diethyl) malonate C, in the presence of a base such as sodium methoxide, at a temperature of between 60 ° C. and 100 ° C. C, as described for example by Badawey E.- SAM et al. (Eur J Med Chem, 1998, 33 (5), 349-361) Compounds E can be obtained from a compound D by treatment with a chlorinating agent such as phosphorus oxychloride, in the absence of solvent, at a temperature between 20 ° C and 120 ° C, or in the presence of a solvent such as dichloroethane, at a temperature between 20 ° C and the boiling point of the solvent, such as under the conditions described by Yamashita, A. et al (Syn. Commun (2004), 34 (5), 795-803) Compounds F can be obtained from a compound E by reaction with morpholine, in the absence of solvent, at a temperature between 20 ° C and 120 ° C, or in the presence of a solvent such as acetonitrile, at a temperature between 20 ° C and the reflux temperature of the solvent, as described for example by Aliabiev SB (Lett Org Chem (2007), 4 (4), 273-280 Compounds (I) can be obtained by addition of a compound G (R1-X with X = Cl, B r, I or OTf) on a mixture of a compound F and a base such as sodium hydride or cesium carbonate in excess, in a solvent such as tetrahydrofuran, N, N-dimethylformamide or acetonitrile, at a temperature between 0 ° C and 80 ° C, as described for example by Ting PC et al. (J. Med Chem (1990), 33 (10), 2697-2706) Alternatively, the compounds (I) can be obtained from a compound J by reaction with morpholine, in the absence of a solvent, at a temperature between 20 ° C and 120 ° C, or in the presence of a solvent, such as acetonitrile, at a temperature between 20 ° C and the reflux temperature of the solvent, as described for example by Aliabiev SB (Lett Org.

Chem. (2007), 4 (4), 273-280. the compounds J can be obtained by adding a compound G (R1-X with X = Cl, Br, I or OTf) to a mixture of a compound E and a base such as sodium hydride or cesium carbonate in excess, in a solvent such as tetrahydrofuran, N, N-dimethylformamide or acetonitrile, at a temperature between 0 ° C and 80 ° C, as described for example by Ting PC et al. (J. Med Chem (1990), 33 (10), 2697-2706). Alternatively, the compounds J can be obtained by Mitsunobu reaction between a compound E and an alcohol H, in the presence of diethyl azodicarboxylate and triphenylphosphine (optionally supported on resin), in a solvent such as tetrahydrofuran, at a temperature of between 0 ° C and 65 ° C, as described for example by Mitsunobu O. et al. (Synthesis (1981), 1-28). In cases where R2 is different from R3 and the synthesis is not stereoselective, the enantiomers or possible diastereoisomers of the synthesis intermediates or compounds (I) can be separated by chromatography on chiral support. The following examples of products of formula (I) illustrate the invention without however limiting it. Among the starting products of formula A, B or C are known and can be obtained either commercially or according to the usual methods known to those skilled in the art, for example from commercial products. It is understood by those skilled in the art that, for the implementation of the methods according to the invention described above, it may be necessary to introduce protective groups of the amino, carboxyl and alcohol functions in order to avoid side reactions. The following non-exhaustive list of examples of protection of reactive functions may be mentioned: the hydroxyl groups may be protected for example by alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyranyl, benzyl or acetyl, - the amino groups may be protected for example by acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC, benzyloxycarbonyl, phthalimido or other radicals known in peptide chemistry. Acid functions may be protected by as esters formed with readily cleavable esters such as benzyl or tert-butyl esters or esters known in peptide chemistry.

A list of different protective groups used in the manuals known to those skilled in the art and for example in the patent FR 2,499,995. It may be noted that it is possible to subject, if desired and if necessary, intermediate products or products of formula (I) thus obtained by the processes indicated above, to obtain other intermediates or other products of formula (I), one or more transformation reactions known to those skilled in the art such as for example: a) an esterification reaction of an acid function, b) an ester functional saponification reaction in the acid function, c) a reduction reaction of the free or esterified carboxy function as an alcohol function, d) a transformation reaction with hydroxyl function, or with hydroxyl function with alkoxy function, e) an elimination reaction of the protective groups which the protected reactive functions can carry, f) a salification reaction with a mineral or organic acid or with a base to obtain the corresponding salt, g) a resolving reaction of the racemic forms into split products, said products of formula (I) thus obtained being in any racemic isomeric possible form , enantiomers and diastereoisomers. The reactions a) to g) can be carried out under the usual conditions known to those skilled in the art such as, for example, those indicated below. a) The products described above may, if desired, be subjected, on the possible carboxy functions, to esterification reactions which may be carried out according to the usual methods known to those skilled in the art. b) The possible acid-functional ester function transformations of the products described above may, if desired, be carried out under the usual conditions known to those skilled in the art, in particular by acid or alkaline hydrolysis, for example with sodium hydroxide or sodium hydroxide. potash in an alcoholic medium such as, for example, in methanol or in hydrochloric or sulfuric acid. The saponification reaction may be carried out according to the usual methods known to those skilled in the art, such as, for example, in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of sodium hydroxide or potassium hydroxide. c) The optional free or esterified carboxy functions of the products described above may, if desired, be reduced according to the alcohol by the methods known to those skilled in the art: the optional esterified carboxy functions may, if desired, be reduced in function alcohol by the methods known to those skilled in the art and in particular by lithium hydride and aluminum in a solvent such as for example tetrahydrofuran or dioxane or ethyl ether. The optional free carboxy functions of the products described above may, if desired, be reduced in particular alcohol function by boron hydride. d) The optional alkoxy functions, such as in particular methoxy, of the products described above may, if desired, be converted into hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as For example, methylene chloride, with hydrobromide or pyridine hydrochloride or with hydrobromic or hydrochloric acid in water or trifluoroacetic acid under reflux. e) The elimination of protective groups such as for example those indicated above can be carried out under the usual conditions known to those skilled in the art, in particular by acid hydrolysis carried out with an acid such as hydrochloric acid, benzene sulfonic acid or para-toluenesulphonic, formic or trifluoroacetic or catalytic hydrogenation.

The phthalimido group can be removed by hydrazine. f) The products described above may, if desired, be the subject of salification reactions, for example by a mineral or organic acid or by a mineral or organic base according to the usual methods known to those skilled in the art: such salification reaction can be carried out for example in the presence of hydrochloric acid for example or tartaric acid, citric or methanesulfonic acid in an alcohol such as for example ethanol or methanol. g) Any optically active forms of the products described above may be prepared by resolution of the racemic agents according to the usual methods known to those skilled in the art. The products of formula (I) as defined above, as well as their addition salts with acids, have interesting pharmacological properties, in particular because of their kinase inhibiting properties as indicated above. The products of the present invention are especially useful for the therapy of tumors. The products of the invention can also increase the therapeutic effects of commonly used anti-tumor agents. These properties justify their application in therapeutics and the invention has particularly as object as medicaments, the products of formula (I) as defined above, said products of formula (I) being in all isomeric forms possible racemic , enantiomers and diastereoisomers, as well as the addition salts with inorganic and organic acids or with the pharmaceutically acceptable inorganic and organic bases of said products of formula (I). The subject of the invention is particularly suitable, as medicaments, the products corresponding to the following formulas: - (2S) -1- [2- (4-methoxyphenyl) ethyl] -2-methyl-7- (morpholin-4- yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - 1- [2- (4-methoxyphenyl) ethyl] -2-methyl-7-yl - (Morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1-benzyl-2-methyl-7 - (Morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4) -yl) -1- (2-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (Morpholin-4-yl) -1- (3-phenylpropyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2- methyl-7- (morpholin-4-yl) -1- (2-phenoxyethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S 2-methyl-7- (morpholin-4-yl) -1- [2- (phenylsulfanyl) ethyl] -2- (trifluoromethyl) -2,3-dihydro-mimidazo [1, 2-a] ] py rimid in-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2R) -2-phenylpropyl] -2- (trifluoromethyl) -2, 3-Dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) -2-phenylpropyl] - 2- (Trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1 - [(2S) -2-hydroxy-2-phenylethyl] -2- methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1 - [(2R) 2-hydroxy-2-phenylethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) - one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) -1-phenylpropan-2-yl] -2- (trifluoromethyl) -2,3-dihydroimidazo [ 1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(1S) -1-phenylpropyl] -2- (Trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(1R) 1-phenylpropyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-) yl) -1- {2- [4 - (Morpholin-4-yl) phenyl] ethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl (7-Morpholin-4-yl) -1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - 1- [ 2- (4-methoxyphenyl) ethyl] -2,2-dimethyl-7- (morpholin-4-yl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one and salts thereof addition with the inorganic and organic acids or with the pharmaceutically acceptable mineral and organic bases of said products of formula (I). The invention also relates to pharmaceutical compositions containing as active principle at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate, optionally, a pharmaceutically acceptable carrier. The invention thus extends to pharmaceutical compositions containing as active principle at least one of the drugs as defined above. Such pharmaceutical compositions of the present invention may also, if appropriate, contain active principles of other antimitotic drugs such as in particular those based on taxol, cisplatin, intercalating agents of DNA and others. These pharmaceutical compositions may be administered orally, parenterally or locally by topical application to the skin and mucous membranes or by intravenous or intramuscular injection.

These compositions may be solid or liquid and may be in any of the pharmaceutical forms commonly used in human medicine, such as, for example, simple or coated tablets, pills, lozenges, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods. The active ingredient can be incorporated into the excipients usually employed in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, the fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various wetting agents, dispersing or emulsifying agents, preservatives. The usual dosage, variable according to the product used, the subject treated and the condition in question, may be, for example, from 0.05 to 5 g per day in the adult, or preferably from 0.1 to 2 g. per day.

The subject of the present invention is also the use of products of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of a protein kinase. Such a medicament may especially be for the treatment or prevention of a disease in a mammal. The present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the prevention or treatment of diseases related to uncontrolled proliferation. The present invention thus particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament for the treatment or prevention of diseases in oncology and in particular for the cancer treatment. Among these cancers, one is interested in the treatment of solid or liquid tumors, in the treatment of cancers resistant to cytotoxic agents. The products of the present invention cited can in particular be used for the treatment of primary tumors and / or metastases in particular in gastric, hepatic, renal, ovarian, colon, prostate, endometrial, lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder, breast cancers, in melanoma , in lymphoid or myeloid hematopoietic tumors, in sarcomas, in cancers of the brain, larynx, lymphatic system, cancers of the bones and pancreas, in hamartomas. The subject of the present invention is also the use of the products of formula (I) as defined above for the preparation of medicaments intended for the chemotherapy of cancers. Such drugs for cancer chemotherapy may be used alone or in combination. The products of the present application may especially be administered alone or in combination with chemotherapy or radiotherapy or in combination with other therapeutic agents, for example. Such therapeutic agents may be commonly used anti-tumor agents. The subject of the present invention is also, as new industrial products, the synthetic intermediates of formulas D, E, F and J as defined above and referred to below: in which R 1, R 2, R 3 and R 4 have the definitions given in any one of claims 1 to 2. The following examples which are products of formula (I) illustrate the invention without however limiting it. D E Experimental Part The nomenclature of the compounds of this invention was carried out with ACDLABS software version 10.0. The microwave oven used is a Biotage device, InitiatorTM 2.0, 5 400W max, 2450 MHz. 1H NMR spectra at 400 MHz and 1H at 500 MHz were carried out on BRUKER AVANCE DRX-400 or BRUKER AVANCE DPX-500 spectrometer with the chemical shifts (8 in ppm) in the solvent dimethylsulfoxide-d6 (DMSO-d6) referenced at 2.5 ppm at the temperature of 10-303K. Mass spectra (SM) were obtained either by Method A or Method B: Method A: WATERS UPLC-SQD Apparatus; Ionization: electrospray in positive and / or negative (ES +/-) mode; Chromatographic conditions: Column: ACQUITY BEH C18 1.7 μm 2.1 x 50 mm; Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid); Column temperature: 50 ° C; Flow rate: 1 ml / min; Gradient (2 min): 5 to 50% B in 0.8 min; 1.2 min: 100% B; 1.85 min: 100% B; 1.95: 5% B; Retention time = Tr (min). Method B: WATERS ZQ Apparatus; Ionisation: electrospray in positive and / or negative mode (ES +/-); Chromatographic conditions: Column: XBridge C18 2.5 μm - 3 x 50 mm; Solvents: A: H2O (0.1% formic acid) B: CH3CN (0.1% formic acid); Column temperature: 70 ° C; Flow rate: 0.9 ml / min; Gradient (7 min): de5 to 100% deBen5,3min, 5.5min: 100% deB, 6.3min: 5% of B; Retention time = Tr (min). Rotational powers (PR) were measured on a model 341 polarimeter from Perkin Elmer. Wavelength: A line of sodium (589 nanometers). Example 1: (S) -1- [2- (4-Methoxy-phenyl) -ethyl] -2-methyl-7-morpholin-4-5-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one Step k: (S) -1- [2- (4-methoxy-phenyl) -ethyl] -2-methyl-7-morpholin-4-yl-2- trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one To a solution of 60 mg of (S) -2-methyl-7-morpholin-4-yl-2-10 trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one in 3 ml of anhydrous N, N-dimethylformamide are added, at room temperature, under argon, 20 mg of sodium hydride. The resulting reaction mixture is then heated to 60 ° C. 0.04 mL of 4-methoxyphenethyl bromide is then added. After one hour of heating and after control by TLC (CH 2 Cl 2 / MeOH: 95/05), the reaction is partial. 10 mg of sodium hydride and 0.04 mL of 4-methoxyphenethyl bromide are then added and the heating is maintained at 60 ° C. After two more hours of heating and after control by TLC (CH 2 Cl 2 / MeOH: 95/05), the reaction is complete. After cooling, 10 ml of cold water and 20 ml of ethyl acetate are added to the resulting mixture. The organic phase is then separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 98/02) to give 54 mg of (S) -1- [2- (4-methoxy-phenyl) -ethyl] -2-methyl-7 -morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one, as an off-white meringue, having the following characteristics: 1 H NMR Spectrum 1.52 (s, 3H); 2.79 (m, 1H); 2.95 (m, 1H); 3.30 to 3.60 (m, 6H); 3.65 (t, J = 4.9 Hz, 4H); 3.72 (s, 3H); 3.84 (d, J = 12.6 Hz, 1H); 4.11 (d, J = 12.6 Hz, 1H) 4.88 (s, 1H); 6.87 (d, J = 8.6 Hz, 2H); 7.14 (d, J = 8.6 Hz, 2H) Mass Spectrometry: Method B Retention time Tr (min) = 4.07 [M + H] +: m / z 439 Rotatory power: PR = +89; C = 0.710mg / 0.5ML DMSO. Step: (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one A mixture of 2.2 g (S) -7-Chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one in 60 mL of morpholine is heated to 120 ° C . After one hour of heating and after control by LC / MS, the reaction is complete. After cooling, the reaction mixture is concentrated under reduced pressure. On the residue obtained, 30 ml of cold water and 150 ml of ethyl acetate are added. The organic phase is then separated, dried over magnesium sulphate, filtered and then concentrated under reduced pressure to give 2.6 g of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro- 1H-Imidazo [1,2-a] pyrimidin-5-one having the following characteristics: Mass Spectrometry: Method B Retention time Tr (min) = 2.53 [M + H] +: m / z 305 ; [M-H] -: m / z 303 Rotatory power: PR = -9.0 + 1-0.6; C = 1.996710mg / 0.5ML DMSO. Step I: (S) -7-Chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one ## STR3 ## two enantiomers of 7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one (9.22 g) was produced by chiral chromatography: stationary phase : Chiralpak AD; mobile phase: EtOH (05%) / MeOH (05%) / heptane (90%). The dextrorotatory enantiomer is concentrated to obtain 4.56 g of (R) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one .

The laevorotatory enantiomer is concentrated to obtain 4.47 g of (S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidine. 5-one, in the form of a white powder, the characteristics of which are as follows: Rotatory power: PR = -70.9 +/- 1.1; C = 2.623mg / 0.5ML DMSO. Mass Spectrometry: Method A Retention Time Tr (min) = 0.51 [M + H] +: m / z 254; [MH] -: m / z 252 Step h: (R, S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5 -one o ~ CF3 CI N

To a suspension of 20 g of (R, S) -7-hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one in 400 ml of 1,2-dichloroethane are added, at room temperature and under argon atmosphere, 20 ml of phosphorus oxychloride. The reaction mixture is then heated to 65 ° C. After two hours of stirring and after control by LC / MS, the reaction is complete. After cooling, the pale yellow solid formed is filtered to give 4.05 g of a first batch of chlorine product S1. The resulting filtrate is evaporated to dryness under reduced pressure and the residue obtained is taken up in 20 ml of cold water and 200 ml of ethyl acetate. On the mixture obtained, 32% sodium hydroxide is added until pH = 5-6. The organic phase is then separated, dried over magnesium sulfate, filtered and concentrated under reduced pressure to give a yellow meringue. This is purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 98/02) to give 12.24 g of a solid S 2. The two batches S1 and S2 which are identical on TLC are combined to give 16.29 g of (R, S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2 -a] pyrimidin-5-one whose characteristics are as follows: Mass Spectrometry: Method A Retention time Tr (min) = 0.51 [M + H] +: m / z 254; [MH] -: m / z 252 Step g: (R, S) -7-hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5 20.7 g of 4-methyl-4-trifluoromethylimidazolidin-2-ylidene amine hydrobromide and 13.7 g of sodium methylate are added to a mixture of 20.4 g of diethyl malonate in 320 ml of methanol. The resulting mixture is refluxed for 18 hours.

After cooling, the reaction mixture is concentrated to dryness under reduced pressure. On the residue obtained, 100 ml of cold water are added. To the resulting slurry is added 25% hydrochloric acid to pH = 5. The suspension obtained is stirred in an ice bath for two hours and then filtered on fritted glass. The insoluble matter is rinsed with water (twice 15 ml) and then dried to give 30 g of (R, S) -7-hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1 H- imidazo [1,2-a] pyrimidin-5-one, in the form of a white solid, the characteristics of which are as follows: Mass Spectrometry: Method B Retention time Tr (min) = 1.29 [M + H] ] +: m / z 236; [MH] -: m / z 234 Step f: (R, S) -4-methyl-4-trifluoromethyl-imidazolidin-2-ylidene amine hydrobromide CF3 On a solution cooled to 5 ° C with 5 g of (R, S) -3,3,3-trifluoro-2-methyl-propane-1,2-diamine in 30 ml of water are added, in small pieces, 3.72 g of cyanogen bromide while maintaining the temperature between 5 and 10 ° C. At the end of the addition, the reaction mixture is left at 5 ° C for 30 minutes. The ice bath is then removed and the reaction mixture stirred at room temperature for 3 hours.

The reaction mixture is then concentrated under reduced pressure. The residue obtained is taken up twice with 200 ml of EtOH and then twice with 200 ml of toluene, with in each case evaporation to dryness. The resulting solid is triturated with ethyl ether and then filtered to give 7 g of (R, S) -4-methyl-4-trifluoromethyl-imidazolidin-2-ylidene amine hydrobromide, in the form of a white solid, of which the characteristics are as follows: Mass spectrometry: method A [M + H] +: m / z = 168.

Stage e: (R, S) -3,3,3-trifluoro-2-methyl-propane-1,2-diamine H 2 N NH 2 CF 3 In a flask, 27 g of the (R, S) -3 hydrochloride are introduced. 3,3-trifluoro-2-methyl-propane-1,2-diamine, 15 mL of water and 400 mL of ethyl ether. With magnetic stirring, 25 ml of 32% sodium hydroxide are added dropwise to the mixture obtained, to pH = 12. The aqueous phase is then decanted and extracted with 4 times 200 ml of ethyl ether. The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (300 mbar / bath temperature = 25 ° C.) to give 21.9 g of (R, S) -3,3,3-trifluoro-2 - methyl-propane-1,2-diamine, in the form of a light yellow oil, the characteristics of which are as follows: Mass spectrometry: Method A [M + H] +: m / z = 143. Stage d: Dihydrochloride (R, S) -3,3,3-trifluoro-2-methyl-propane-1,2-diamine, 2HCl, 2HCl H 2 N NH 2 CF 3. In an autoclave, 8 g of palladium hydroxide at 20 ° C. were charged. %, 58 g of (R, S) -N-benzyl-3,3,3-trifluoro-2-methyl-propane-1,2-diamine in 200 ml of methanol and 183 ml of 3N hydrochloric acid. The resulting mixture is hydrogenated at 5 bar hydrogen pressure at 22 ° C for 48 hours.

The resulting mixture is then filtered and the filtrate is concentrated under reduced pressure. The residue obtained is taken up twice with 300 ml of EtOH and then twice with 300 ml of toluene, with dry evaporation in each case. There is thus obtained 50 g of (R, S) -3,3,3-trifluoro-2-methylpropane-1,2-diamine dihydrochloride, in the form of an off-white meringue, the characteristics of which are as follows: : Mass Spectrometry: method A [M + H] +: m / z = 143 Stage c: (R, S) -N-benzyl-3,3,3-trifluoro-2-methyl-propane-1,2- diamine Ph HN In a three-necked mixture under argon, are added in small portions to a solution of 23 g of (R, S) -N-benzylamino-3,3,3-trifluoro-2-methylpropionitrile in 1000 ml of ethyl ether anhydrous cooled at 4 ° C., 15.5 g of lithium aluminum hydride. A strong evolution of gas with elevation of the temperature to 8 ° C. is observed. At the end of the addition, the temperature is allowed to rise to room temperature and the mixture is allowed to stir at ambient temperature for 18 hours. The resulting reaction mixture is cooled to 4 ° C before adding 20 ml of water, dropwise and very slowly. Strong gaseous evolution is observed with raising the temperature to 12 ° C. Still at 4 ° C, 20 ml of 15% potassium hydroxide are added dropwise and very slowly to the mixture obtained, then 40 ml of water are added dropwise and very slowly. The resulting white precipitate is filtered and the filtrate is dried over magnesium sulfate and then concentrated under reduced pressure to give 22.5 g of (R, S) -N-benzyl-3,3,3-trifluoro-2-methyl-propane. 1,2-diamine, in the form of a colorless oil, the characteristics of which are as follows: Mass spectrometry: method A [M + H] +: m / z = 233 Stage b: 2-benzylamino-3,3 , 3-trifluoro-2-methyl-propionitrile CF336 Ph J HN

Embedded image CN In a three-necked mixture under argon, a solution of 80 g of (R, S) -N-benzyl- [2,2,2-trifluoro-1-methyl-ethyl- (E)] is added dropwise. ylidene] -amine in 800 ml of dichloromethane, cooled to -70 ° C., 59.17 g of trimethylsilyl cyanide and then, drop by drop, 84.65 g of boron trifluoroetherate. The temperature rises to -63 ° C and the solution becomes orange. After addition, the reaction mixture is stirred at -63 ° C for 30 minutes. The dry ice bath is then removed to allow the temperature to rise to room temperature. The reaction mixture is then stirred at room temperature overnight. The saturated sodium bicarbonate solution is then added to the resulting mixture until the pH is 8. The organic phase is then separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by filtration on silica (eluent: dichloromethane / cyclohexane: 25/75) to give 48 g of (R, S) -2-benzylamino-3,3,3-trifluoro-2-methyl-propionitrile, under form of a colorless oil, whose characteristics are as follows: Mass Spectrometry: the spectra were made by electronic impact on WATERS GCTof apparatus (direct introduction without LC). El: [M] +. m / z 228; m / z 91 (base peak) Step a: benzyl- [2,2,2-trifluoro-1-methyl-eth- (E) -ylidene] -amine C 3 ~ In a tricol, add, dropwise on a solution of 157 g of trifluoroacetone in 600 ml of toluene, cooled to 5 ° C., 100 g of benzylamine. The temperature rises to 25 ° C.

9.4 g of pyridinium para-toluene sulphonate are then added all at once. The resulting reaction mixture is stirred at room temperature for 30 minutes. A condenser surmounted by a Dean-Stark is then installed and the reaction mixture is refluxed for 4 hours, during which time 25 ml of water are collected.

After cooling, the solid formed is filtered and the filtrate is concentrated under reduced pressure to give 150 g of [2,2,2-trifluoro-1-methyl-eth- (E) -ylidene] -amine, in the form of a colorless liquid, the characteristics of which are as follows: Mass Spectrometry: The spectra were made by electronic impact on the WATERS GCTof apparatus (direct introduction without LC). El: [M] +. : m / z 201; m / z 91 (base peak) Alternatively, (S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one can be prepared in the following manner: Step h ': (S) - 7-Chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one o F3 To a suspension of 5.6 g of (S) -7-hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one in 100 mL of 1 2 ml of phosphorus oxychloride are added at room temperature under an argon atmosphere, 2-dichloroethane. The resulting mixture is then heated to 70 ° C. After two hours of stirring and after control by LC / MS, the reaction is complete. After cooling, the reaction mixture is evaporated to dryness under reduced pressure. The residue obtained is taken up in 5 ml of cold water and 200 ml of ethyl acetate. 32% sodium hydroxide is added to the mixture obtained to the pH of 6. The organic phase is then separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure to give 6 g of the (S) -7- chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: Mass Spectrometry: Method A Time of retention Tr (min) = 0.51 [M + H] +: m / z 254; [M-H] -: m / z 252 Rotatory power: PR = -64.8 + 1-1.1; C = 2.2mg / 0.5ML DMSO. Stage g ': (S) -7-Hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one F3 On a mixture of 5.4 g of malonate of diethyl in 50 ml of methanol are added 8.4 g of (S) -4-methyl-4-trifluoromethyl-imidazolidin-2-ylidene amine hydrobromide and 2.16 g of sodium methoxide. The resulting mixture is refluxed for 18 hours. After cooling, the mixture obtained is concentrated to dryness under reduced pressure. 20 ml of cold water are added to the residue obtained to obtain a slurry on which 25% hydrochloric acid is added until pH = 5.

The resulting suspension is stirred in an ice bath for two hours and then filtered on fritted glass. The insoluble material obtained is rinsed with water (twice 4 ml) and then dried to give 5.6 g of (S) -7-hydroxy-2-methyl-2-trifluoromethyl-2,3-dihydro-1 H- imidazo [1,2-a] pyrimidin-5-one, in the form of a white solid, the characteristics of which are as follows: Mass Spectrometry: Method A Retention time Tr (min) = 0.32 [M + H] ] +: m / z 236; [M-H] -: m / z 234 Rotatory power: PR = -5.6 +/- 0.6; C = 1.789mg / 0.5ML MeOH.

Step f ': (S) -4-Methyl-4-trifluoromethyl-imidazolidin-2-ylidene amine NH 2 HBr HN N1-L-CF3 hydrobromide On a cooled solution at 5 ° C of 2.3 g of S) -3,3,3-trifluoro-2-methyl-propane-1,2-diamine in 10 ml of water, 1.7 g of cyanogen bromide are added in small pieces while maintaining the temperature between 5 and 10 ° C. At the end of the addition, the reaction mixture is left at 5 ° C for 30 minutes. The ice bath is then removed and the resulting mixture is stirred at room temperature for 3 hours. The resulting mixture is then concentrated under reduced pressure. The residue obtained is taken up twice with 100 ml of ethanol and then twice with 100 ml of toluene, with each time evaporating to dryness. The solid obtained is triturated with ethyl ether and then filtered to give 4.5 g of (S) -4-methyl-4-trifluoromethyl-imidazolidin-2-ylidene amine hydrobromide in the form of a white solid, characteristics are as follows: Mass Spectrometry: Method A Retention time Tr (min) = 0.14 [M + H] +: m / z 168 Rotatory power: PR = -5.2 +/- 0.3; C = 4.909mg / 0.5ML DMSO. Step e ': (S) -3,3,3-Trifluoro-2-methyl-propane-1,2-diamine H 2 N NH 2 CF 3 In a flask, 4.8 g of the (S) -3,3 hydrochloride, 3-trifluoro-2-methyl-propane-1,2-diamine, 2.5 mL of water and 100 mL of ethyl ether. 4.5 ml of 32% sodium hydroxide solution up to pH = 12 are added dropwise to the resulting mixture. The aqueous phase is then decanted and then extracted with 4 times 200 ml of ethyl ether.

The organic phases are combined, dried over magnesium sulphate, filtered and then concentrated under reduced pressure (300 mbar / bath temperature = 25 ° C.) to give 2.3 g of 3,3,3-trifluoro-2-methylpropane-1, 2-diamine, in the form of a light yellow oil, the characteristics of which are as follows: Mass Spectrometry: Method B Retention time Tr (min) = 0.34 [M + H] +: m / z 143; base peak: m / z 126 Rotatory power: PR = -4.3 +/- 0.6; C = 1.778mg / 0.5ML DMSO. Stage of: (S) -3,3,3-Trifluoro-2-methyl-propane-1,2-diamino dihydrochloride, 2HCl H 2 N. CF, NH2 In an autoclave, a mixture of 7 g of (R) -2 - ((S) -1-aminomethyl-2) is hydrogenated at 22 ° C. under a hydrogen pressure of 5 bar and for 18 hours. 2,2-trifluoro-1-methyl-ethylamino) -2-phenylethanol in 40.5 mL of methanol, 23.5 mL of 3N hydrochloric acid and 0.94 g of Pd (OH) 2 / C (20% w / w). The mixture obtained is then filtered and the filtrate evaporated to dryness. The oil obtained is taken up in a 3N hydrochloric acid solution (50 ml). The resulting mixture is extracted with diethyl ether (3 x 50 mL). The aqueous phase is then evaporated to dryness, taken up with methanol and then evaporated to dryness again. The yellowish solid obtained is dried under vacuum to yield 5.54 g (79%) of (S) -3,3,3-trifluoro-2-methyl-propane-1,2-diamine dihydrochloride, in the form of a off-white solid, whose characteristics are as follows: 1H NMR Spectrum (400 MHz, D20): 1.55 (s, 3H), 3.40 (d, J = 14.6 Hz, 10 1 H), 3.51 (d, J = 14.6) Hz, 1H). 19 F NMR (400 MHz, D 2 O): - 81.08 (not calibrated with C 6 F 6) [?] D: + 4.65 (C 2.2, CH 3 OH) Step c ': (R) -2 - ((S) -1-Aminomethyl-2 2,2-trifluoro-1-methyl-ethylamino) -2-phenyl-ethanol 1.6 g of lithium aluminum hydride are added in small portions under argon to a solution cooled to 4 ° C. in small portions, 2.5 g of (S) -3,3,3-trifluoro-2 - ((R) -2-hydroxyoxy-1-phenyl-ethylamino) -2-methylpropionitrile in 250 mL of anhydrous ethyl ether. Strong gas evolution is observed with raising the temperature to 8 ° C. At the end of the addition, the temperature is allowed to rise to ambient temperature and the reaction mixture is left stirring for 18 h. The mixture obtained is cooled to 4 ° C. before addition, dropwise and very slowly, of 2 ml of water. A strong evolution of gas is observed with raising the temperature to 12 ° C. To the resulting mixture maintained at 4 ° C, 2 ml of 15% potassium hydroxide solution is added dropwise and very slowly followed by 4 ml of water dropwise and very slowly. The white precipitate formed is filtered off and the filtrate obtained is dried over magnesium sulphate and then concentrated under reduced pressure to give 2.2 g of (R) -2 - ((S) -1-aminomethyl-2,2,2-trifluoro-1 -methyl-ethylamino) -2-phenylethanol, the characteristics of which are as follows: Mass spectrometry: method A Retention time Tr (min) = 0.43 [M + H] +: m / z 263 Rotatory power: PR = - 51.2 +/- 1.3; C = 1.576 mg / 0.5ML DMSO. Step b ': (S) -3,3,3-Trifluoro-2 - ((R) -2-hydroxy-1-phenyl-ethylamino) -2-methyl-propionitrile Ph Ph HN ~OH and HN / - In a knit under argon, 5.3 g of (R) -2-methyl-4-phenyl-2-trifluoromethyloxazolidine are added dropwise to a solution cooled at 0 ° C. in 100 ml of toluene. ml of dichloromethane, 3.4 g of trimethysilyl cyanide, then dropwise 4.9 g of boron trifluoro etherate. The cold bath is then removed to allow the temperature to rise to room temperature.

The resulting mixture is stirred at room temperature for 18 hours before adding a saturated solution of sodium bicarbonate up to pH = 8. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: cyclohexane / AcOEt: 80/20) to give 3 g of (R) -3,3,3-trifluoro-2 - ((R) -2-hydroxy-1 phenyl-ethylamino) -2-methyl-propionitrile, in the form of a colorless oil and 2.5 g of (S) -3,3,3-trifluoro-2 - ((R) -2-hydroxy-1-phenyl-ethylamino 2-methyl-propionitrile, in the form of a white solid, whose characteristics are: Mass Spectrometry: Method A Retention time Tr (min) = 0.86 [M + H] +: m / z 259; [M-H + HCO2H] -: m / z 303 Rotatory power: PR = -89.0 +/- 1.4; C = 2.440mg / 0.5ML CHCl3 and PR = -77.6 + 1-1.4; C = 1.818mg / 0.5ML DMSO. Stage a ': (R, S) -2-Methyl-4- (R) -phenyl-2-trifluoromethyl-oxazolidine Ph CF3 In a tricolor topped with a Dean-Stark, it is added to a solution of 5 g of trifluoroacetone in 180 ml of toluene, 4.8 g of (R) -phenylglycinol then, all at once, 0.8 g of pyridinium para-toluene sulfonate acid. The mixture obtained is then refluxed for 18 hours during which time 0.3 ml of water is collected.

After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by filtration on silica (eluent: dichloromethane) to give 5.3 g of (R, S) -2-methyl-4- (R) -phenyl-2-trifluoromethyl-oxazolidine, in the form of a liquid. colorless, the characteristics of which are as follows: Mass spectrometry: method A Retention time Tr (min) = 0.96 [M + H] +: m / z 232 Rotatory power: PR = -23.4 + 1-0.8; C = 1.794mg / 0.5ML CH3OH. Example 2: (R, S) -1- [2- (4-Methoxyphenyl) ethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1 The product is prepared by following the procedure described in Example 1, starting from 120 mg of (R, S) -2-methyl-7-morpholin-2-methyl-7-morpholinol. 4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one (prepared according to the procedure of Example 1j but from (R, S) 7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one described in Example 1 h) and 420 mg of bromide. 4-methoxyphenethyl. After purification by chromatography on silica (eluent: gradient from 0% to 20% of the eluent CH 2 Cl 2 / MeOH / NH 4 OH 28% 38/17/2 in dichloromethane), 80 mg of (R, S) -1 are obtained. [2- (4-methoxy-phenyl) -ethyl] -2,6-dimethyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1 H NMR spectrum: 1.52 (br s, 3 H); 2.73 to 2.84 (m, 1H); 2.90 to 3.01 (m, 1H); 3.36-3.59 (m, 6H); 3.61 to 3.68 (m, 4H); 3.72 (s, 3H); 3.84 (d, J = 12.5 Hz, 1H); 4.11 (d, J = 12.5 Hz, 1H); 4.88 (s, 1H); 6.87 (d, J = 8.6 Hz, 2H); 7.14 (d, J = 8.6 Hz, 2H) Mass Spectrometry: Method A Retention Time Tr (min) = 0.96 [M + H] +: m / z 439 Example 3: (S) 1-Benzyl-2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one 45 The product is prepared in following the procedure described in Example 1 starting from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1, 2-a] pyrimidin-5-one (Example 1j) and 281 mg of benzyl bromide, replacing the sodium hydride by cesium carbonate and adding 10 mg of benzyl triethylammonim chloride (BTEAC). After purification by chromatography on a silica column (eluent: dichloromethane / methanol 98/02), 70 mg of (S) -1-benzyl-2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2 are obtained. 3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR Spectrum: 1.60 (s, 3H); 3.34 (partially masked m, 4H); 3.54 (m, 4H); 3.97 (d, J = 12.5 Hz, 1H); 4.16 (d, J = 12.5 Hz, 1H); 4.57 (d, J = 16.4 Hz, 1H); 4.77 (d, J = 16.4Hz, 1H); 4.89 (s, 1H); 7.20 to 7.45 (m, 5 H) Mass Spectrometry: Method B Retention time Tr (min) = 3.89 [M + H] +: m / z 395 Rotatory power: PR = -20.9 +/- 0.8; C = 1.829mg / 0.5ML DMSO. Example 4: (S) -2-methyl-7-morpholin-4-yl-1-phenethyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one product is prepared by following the procedure described in Example 1, starting from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H imidazo [1,2-a] pyrimidin-5-one (Example 1j) and 304 mg of (2-bromoethyl) benzene, replacing the sodium hydride with cesium carbonate and, adding 10 mg of chloride benzyl triethylammonim (BTEAC). After purification by chromatography on a silica column (eluent: dichloromethane / methanol 98/02), 120 mg of (S) -2-methyl-7-morpholin-4-yl-1-phenethyl-2-trifluoromethyl-2 are obtained. 3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum (400MHz, ppm: DMSO-d6): 1.52 (s, 3H), 2.79 to 2.91 (m, 1H); 2.97 to 3.08 (m, 1H); 3.40-3.51 (m, 5H); 3.54 to 3.68 (m, 1H); 3.64 (t, J = 4.8 Hz, 4H); 3.84 (d, J = 12.5 Hz, 1H); 4.11 (d, J = 12.5 Hz, 1H); 4.88 (s, 1H); 7.20 to 7.26 (m, 3H); 7.27 to 7.37 (m, 2 H) Mass Spectrometry: Method B Retention time Tr (min) = 4.14 [M + H] +: m / z 409 Rotatory power: PR = -34.8 + 1-0.8; C = 2.558mg / 0.5ML DMSO. Example 5: (S) -2-Methyl-7-morpholin-4-yl-1- (3-phenyl-propyl) -2-20-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] Pyrimidin-5-one The product is prepared following the procedure described in Example 1, starting from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl. -2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one (Example 1j) and 131 mg of 1-bromo-3-phenylpropane, replacing sodium hydride with cesium carbonate. After purification by chromatography on a silica column (eluent: 97/03 dichloromethane / methanol), 100 mg of (S) -2-methyl-7-morpholin-4-yl-1- (3-phenylpropyl) are obtained 2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.61 (s, 3H); 1.83 to 2.02 (m, 2H); 2.62 (t, J = 7.3 Hz, 2H); 3.26 to 3.42 (partially masked m, 6H); 3.56 to 3.62 (m, 4H); 3.86 (d, J = 12.5 Hz, 1H); 4.08 (d, J = 12.5 Hz, 1H); 4.82 (s, 1H); 7.14 to 7.23 (m, 3H); 7.24 to 7.33 (m, 2H).

Mass Spectrometry: Method B Retention time Tr (min) = 4.27 [M + H] +: m / z 423 Rotatory power: PR = -1.5 +/- 0.4; C = 2.576mg / 0.5ML DMSO. Example 6: (S) -2-methyl-7-morpholin-4-yl-1- (2-phenoxy-ethyl) -2-20 trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one. The product is prepared following the procedure described in Example 1, starting from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro 1 H-imidazo [1,2-a] pyrimidin-5-one (Example 1j) and 143 mg of (2-bromoethyl) phenyl ether, replacing the sodium hydride with cesium carbonate . After purification by chromatography on a silica column (eluent: dichloromethane / methanol 97/03), 124 mg of (S) -2-methyl-7-morpholin-4-yl-1- (2-phenoxyethyl) are obtained. 2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.69 (s, 3H); 3.35 to 3.44 (m, 4H); 3.59 (t, J = 4.7 Hz, 4H); 3.63 to 3.73 (m, 1H); 3.74 to 3.86 (m, 1H); 3.92 (d, J = 12.5 Hz, 1H); 4.10 to 4.30 (m, 3H); 4.88 (s, 1H); 6.83 to 7.00 (m, 3H); 7.24 to 7.32 (m, 2H). Mass Spectrometry: Method A Retention time Tr (min) = 0.95 [M + H] +: m / z 425 Example 7: (S) -2-methyl-7-morpholin-4-yl-1- ( 2-phenylsulfanyl-ethyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one The product is prepared following the procedure described in Example 1, at from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one (example 1j) and 143 mg of 2-bromoethyl phenyl sulfide, replacing the sodium hydride with cesium carbonate. After purification by chromatography on a silica column (eluent: dichloromethane / methanol 97/03), 96 mg of (S) -2-methyl-7-morpholin-4-yl-1- (2-phenylsulfanyl-ethyl) are obtained 2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1 H NMR spectrum: 1.62 (s, 3H); 3.05 to 3.17 (m, 1H); 3.20 to 3.34 (m, 5H); 3.40 to 3.51 (m, 1H); 3.55 to 3.64 (s, 5H); 3.83 (d, J = 12.5 Hz, 1H); 4.10 (d, J = 12.5 Hz, 1H); 4.86 (s, 1H); 7.26 (t, J = 7.5 Hz, 1H); 7.34 (t, J = 7.5 Hz, 2H); 7.44 (d, J = 7.5 Hz, 2H).

Mass spectrometry: method A Retention time Tr (min) = 1.01 [M + H] +: m / z 441 Example 8: (S) -2-methyl-7-morpholin-4-yl-1- ( (R) -2-phenyl-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one The product is prepared following the procedure described in US Pat. Example 1, starting from 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidine 5-one (Example 1j) and 143 mg of 1-bromo-2-phenylpropane, replacing the sodium hydride with cesium carbonate. After purification by chromatography on a silica column (eluent: 97/03 dichloromethane / methanol), 100 mg of (2S) -2-methyl-7-morpholin-4-yl-1 - ((R and S) -2 are obtained phenylpropyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one. The separation of the two diastereoisomers of (2S) -2-methyl-7-20-morpholin-4-yl-1- (2-phenyl-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1] , 2-a] pyrimidin-5-one was performed by chiral chromatography: stationary phase: Chiralpak AD, mobile phase: EtOH (04%) / MeOH (01%) / Heptane (95%). The first diastereoisomer is concentrated to give 17 mg of 25 (S) -2-methyl-7-morpholin-4-yl-1 - ((R) -2-phenyl-propyl) -2-trifluoromethyl-2,310 dihydro 1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.25 (d, J = 6.4 Hz, 3H); 1.68 (s, 3H); 3.32-3.51 (m, 7H); 3.60 to 3.67 (m, 4H); 3.91 (d, J = 12.4 Hz, 1H); 4.12 (d, J = 12.4 Hz, 1H); 4.87 (s, 1H); 7.20 to 7.24 (m, 1H); 7.25 to 7.36 (m, 4H). Mass Spectrometry: Method A Retention time Tr (min) = 1.01 [M + H] +: m / z 423 Example 9: (S) -2-methyl-7-morpholin-4-yl-1 (2 S) -2-phenyl-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one n F3 The second diastereoisomer obtained in Example 8 is concentrated to give 19 mg of (S) -2-methyl-7-morpholin-4-yl-1 - ((S) -2-phenylpropyl) -2-trifluoromethyl-2,3-dihydrogen. 1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.08 (s, 3H); 1.26 (d, J = 6.8 Hz, 3H); 3.35 to 3.70 (m, 12H); 4.05 (d, J = 12.7 Hz, 1H); 4.88 (s, 1H); 7.18 to 7.25 (m, 3H); 7.27 to 7.34 (m, 2H). Mass Spectrometry: Method A Retention time Tr (min) = 1.01 [M + H] +: m / z 423 Example 10: (S) -1 - ((S) -2-hydroxy-2-phenyl- ethyl) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one The product is prepared by following the procedure described in Example 1, starting from 200 mg of (R, S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1] , 2-a] pyrimidin-5-one (prepared following the procedure of Example 1j but starting from (R, S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro- 1 H-imidazo [1,2-a] pyrimidin-5-one described in Example 1h) and 0.4 mL of (S) -2-chloro-1-phenylethanol, replacing the sodium hydride by cesium carbonate and adding 10 mg of benzyl triethylammonim chloride (BTEAC). After purification by preparative LC / MS and then returning to the base by passage through a silica column (eluent: dichloromethane / methanol / triethylamine 98/02 / 0.5), 100 mg of (S) -1 - ((S) - are obtained. 2-hydroxy-2-phenylethyl) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5- the characteristics of which are as follows: 1H NMR spectrum: 1.71 (s, 3H); 3.17 (dd, J = 9.7 and 14.4 Hz, 1H); 3.40-3.52 (m, 4H); 3.56 (dd, J = 2.9 and 14.4 Hz, 1H); 3.65 (t, J = 4.9 Hz, 4H); 3.85 (d, J = 12.5 Hz, 1H); 4.18 (d, J = 12.5 Hz, 1H); 4.90 (s, 1H); 5.06 to 5.15 (m, 1H); 5.60 (d, J = 4.4 Hz, 1H); 7.23 to 7.43 (m, 5H). Mass Spectrometry: Method A Retention Time Tr (min) = 0.85 [M + H] +: m / z 425; [MHCO 2 H-H] -: m / z 469 Rotatory power: PR = -45.1 + 1-1.0; C = 2.151mg / 0.5ML DMSO.

The purifications above also lead to 36 mg of the second diastereoisomer, (R) -1 - ((S) -2-hydroxy-2-phenyl-ethyl) -2-methyl-7-morpholin-4-yl-2 trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one.

Example 11: (S) -1 - ((R) -2-Hydroxy-2-phenyl-ethyl) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H- imidazo [1,2-a] pyrimidin-5-one 0 N '' (CF3

The product is prepared by following the procedure described in Example 1, starting from 275 mg of (R, S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2, 3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one (prepared according to the procedure of Example 1 but from (R, S) -7-chloro-2-methyl); 2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one described in Example 1h) and 0.155 ml of (R) -2-chloro-1-phenylethanol After purification by chromatography on a silica column (eluent: dichloromethane / methanol 97/03) and then purification by preparative LC / MS and return to the base by passage through a column of silica (eluent: dichloromethane / methanol / triethylamine 98/02 / 0.5), 40 mg of (S) -1 - ((R) -2-hydroxy-2-phenyl-ethyl) -2-methyl-7-morpholin-4-yl-2- is obtained.

trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.10 (s, 3H); 3.25 (dd, J = 6.8 and 13.5 Hz, 1H); 3.38 to 3.49 (m, 4H); 3.64 (m, 6H); 4.07 (d, J = 12.5 Hz, 1H); 4.88 (s, 1H); 5.05 to 5.13 (m, 1H); 5.55 (d, = 4.2 Hz, 1H); 7.20 to 7.45 (m, 5H).

Mass Spectrometry: Method B Retention time Tr (min) = 3.48 [M + H] +: m / z 425; [M + HCO2H-H] -: m / z 469 Rotatory power: PR = + 75.0 + 1-1.4; C = 1.794mg / 0.5ML DMSO. The above purifications also lead to a second diastereoisomer, (R) -1 - ((R) -2-hydroxy-2-phenyl-ethyl) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl. -2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one. Example 12: (2S) -2-Methyl-1 - ((R) or (S) -1-methyl-2-phenyl-ethyl) -7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro 1 H-imidazo [1,2-a] pyrimidin-5-one to a solution of 400 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro 1 H-imidazo [1,2-a] pyrimidin-5-one (Example 1j) in 5 mL of toluene is added, at room temperature and under an argon atmosphere, a solution of 800 mg of sodium hydroxide in 5 mL of water then 90 mg of tetrabutylammonium hydrogen sulfate and 524 mg of (R, S) -2-bromo-1-phenylpropane in 5 ml of tetrahydrofuran. The resulting mixture is then heated at 60 ° C for eighteen hours. After cooling, 50 ml of ethyl acetate and a saturated aqueous solution of sodium chloride are added to the resulting mixture. The organic phase is separated and then dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH: 97/03) to give 110 mg of a residue which is purified on a chiral column: conditions: stationary phase: Chiralpak IA; mobile phase: EtOH (05%) / heptane (95%) then, second stationary phase: Hypersil C18 Elite, mobile phase: ACN (40%) / H2O (60%). 2-methyl-1- (1-methyl-2-phenyl-ethyl) -7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidine -5-one, in the form of a single diastereoisomer of indeterminate configuration on the phenethyl chain and whose characteristics are as follows: 1 H NMR spectrum: 1.31 (d, J = 6.8 Hz, 3 H); 1.66 (s, 3H); 3.01 to 3.13 (m, 1H); 3.35 to 3.43 (m, 1H); 3.45 to 3.49 (m, 4H); 3.65 to 3.71 (m, 4H); 3.74 (s, 1H); 3.87 (d, J = 12.2 Hz, 1H); 4.06 (d, J = 12.2 Hz, 1H); 4.86 to 4.92 (m, 1H); 7.15 to 7.25 (m, 3H); 7.28-7.35 (m, 2H) Mass Spectrometry: Method B Retention time Tr (min) = 4.30 [M + H] +: m / z 423 Example 13: (S) -2- methyl-7-morpholin-4-yl-1 - ((R) or (S) -1-phenylpropyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5 The chromatographic separation described above, in Example 12, also gave 11.2 mg of a first diastereoisomer of (S) -2-methyl-7-morpholin-4-yl-1 - (1 - phenyl-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one, of undetermined configuration on the benzyl chain, the characteristics of which are as follows: Spectrum 1H NMR: 0.90 (t, J = 7.5 Hz, 3H); 1.57 (s, 3H); 2.34 to 2.47 (m, 2H); 3.39 (m, 4H); 3.62 (m, 4H); 3.86 (d, J = 12.7 Hz, 1H); 4.13 (d, J = 12.7 Hz, 1H); 4.48 (t, J = 7.5 Hz, 1H); 4.88 (s, 1H); 7.25 (t, J = 7.5 Hz, 1H); 7.30-7.36 (t, J = 7.5Hz, 2H); 7.55 (d, J = 7.5 Hz, 2H) NMR Mass Spectrometry: Method B Retention time Tr (min) = 4.25 [M + H] +: m / z 423 Example 14: (S) -2-methyl-7-morpholin-4-yl-1 - ((S) or (R) -1-phenyl-5-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [ 1,2-a] pyrimidin-5-one The chiral separation described above, in Example 12, also gave 40.5 mg of the second diastereoisomer of (S) -2-methyl-7-morpholin-4-yl 1- (1-phenyl-propyl) -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one, indeterminate configuration on the benzyl chain, the characteristics of which are as follows: 1H NMR Spectrum: 0.89 (t, J = 7.5 Hz, 3H); 1.71 (s, 3H); 1.94 to 2.08 (m, 1H); 2.52 to 2.59 (m, 1H); 3.38 (m, 4H); 3.61 (m, 4H); 3.98 (d, J = 12.7 Hz, 1H); 4.12 (d, J = 12.7 Hz, 1H); 4.50 (dd, J = 7.1 and 8.6 Hz, 1H); 4.92 (s, 1H); 7.21 (t, J = 7.5 Hz, 1H); 7.29 (t, J = 7.5 Hz, 2H); 7.55 (d, J = 7.5 Hz, 2H) Mass Spectrometry: Method B Retention time Tr (min) = 4.14 [M + H] +: m / z 423 Example 15: (S 2-methyl-7-morpholin-4-yl-1- [2- (4-morpholin-4-ylphenyl) -ethyl] -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-di] -a] pyrimidin-5-one To a solution of 100 mg of (S) -2-methyl-7-morpholin-4-yl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2] a) pyrimidin-5-one (example 1j) in 5 ml of tetrahydrofuran are added 135 mg of 2- (4-morpholinophenyl) ethanol and 223 mg of polymer-supported triphenylphosphine (3 mmol / g). After stirring for five minutes at room temperature, 0.12 ml of diethyl azodicarboxylate is added. The resulting reaction mixture is then stirred overnight at room temperature. After filtration, the filtrate is evaporated under reduced pressure. The residue obtained is purified by chromatography on a silica column (eluent: 97/03 dichloromethane / methanol) to give 40 mg of (S) -2-methyl-7-morpholin-4-yl-1- [2- ( 4-morpholin-4-yl-phenyl) -ethyl] -2-trifluoromethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR spectrum: 1.53 (s, 3H); 2.70 to 2.81 (m, 1H); 2.86 to 2.98 (m, 1H); 3.02 to 3.08 (m, 4H); 3.35 to 3.58 (m, 6H); 3.62 to 3.67 (m, 4H); 3.70 to 3.75 (m, 4H); 3.84 (d, J = 12.5 Hz, 1H); 4.11 (d, J = 12.5 Hz, 1H); 4.88 (s, 1H); 6.88 (d, J = 8.6 Hz, 2H); 7.08 (d, J = 8.6 Hz, 2H) Mass Spectrometry: Method A Retention Time Tr (min) = 0.87 [M + H] +: m / z 494; [M + 2H] 2 +: m / z 247.5 (base peak) Example 16 (2S) -2-methyl-7- (morpholin-4-yl) -1 - ((R) and (S) - 1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one F3 Step b: In a flask, 190 mg of the (S) - 7-chloro-2-methyl-1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one and 3 mL of morpholine. The resulting mixture is heated at 80 ° C for 30 minutes. After cooling, the reaction mixture is concentrated under reduced pressure. The residue is purified by chromatography on silica (eluent: CH2Cl2 / MeOH 97.5 / 2.5) to give 28 mg of a mixture 1/2 of the two disteroisomers of (2S) -2-methyl-7- (morpholin-4-yl) ) -1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one having the following characteristics: 1H NMR spectrum: Mixture 2 / 3 - 1/3 of diastereoisomers with: 1.74 to 1.79 (m, 5H); 1.82 (d, J = 7.0 Hz, 1H); 3.16 to 3.26 (m, 4H); 3.41 to 3.56 (m, 4H); 3.91 to 4.02 (m, 1H); 4.13 (d, J = 12.5 Hz, 0.65 H); 4.17 (d, J = 12.5 Hz, 0.35 H); 4.79 (s, 0.65H); 4.85 (s, 0.35 H); 4.86 to 4.94 (m, 1H); 7.16 to 7.26 (m, 1H); 7.27 to 7.35 (m, 2H); 7.42 (d, J = 7.8 Hz, 1.3H); 7.46 (d, J = 7.8 Hz, 0.7 H) Mass Spectrometry: Method A Retention time Tr (min) = 0.93 and 0.94 with 2/3 to 1/3 mixture of diastereoisomers [M + H] +: m / z 409 Step a: In a flask, 200 mg of (S) -7-chloro-2-methyl-2-trifluoromethyl-2,3-dihydro-1H-imidazo [ 1,2-a] pyrimidin-5-one prepared (Example 1 i) in 5 mL of tetrahydrofuran, 192 mg of (R, S) -phenyl ethanol and 537 mg of polymer-supported triphenylphosphine (3 mmol / g).

After stirring for 5 minutes at room temperature, 275 mg of diethyl (E) -diazene-1,2-dicarboxylate (DIAD) are added. The reaction mixture is then stirred for 4 hours at room temperature before filtration. The filtrate is then concentrated under reduced pressure and the residue is purified by chromatography on silica (eluent: CH 2 Cl 2 / AcOEt: 96/04) to give 200 mg of a 90/10 mixture of the two diastereoisomers of the (S) -7- chloro-2-methyl-1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one having the following characteristics: Mass: Method B Retention time Tr (min) = 4.56 and 4.47 (mixture of 15 diastereoisomers 90% -10%) [M + H] +: m / z 358 Example 17: 1- [2- ( 4-Methoxy-phenyl) -ethyl] -2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one o : 1- [2- (4-Methoxy-phenyl) -ethyl] -2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin 5-one The product is prepared following the procedure described in Example 1, starting from 100 mg of 2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo [ 1,2-a] pyrimidin-5-one and 0.94 mL of 4-methoxyphenol bromide thyle, replacing sodium hydride with cesium carbonate. After purification by chromatography on a silica column (eluent: dichloromethane / methanol: 98/02), 39 mg of 1- [2- (4-methoxyphenyl) ethyl] -2,2-dimethyl-7-morpholin is obtained. 4-yl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: 1H NMR Spectrum: 1.21 (s, 6H); 2.83 (t, J = 7.7 Hz, 2H); 3.32-3.38 (m, 2H); 3.40 to 3.45 (m, 4H); 3.59 (s, 2H); 3.61 to 3.65 (m, 4H); 3.72 (s, 3H); 4.78 (s, 1H); 6.86 (d, J = 8.6 Hz, 2H); 7.14 (d, J = 8.6 Hz, 2H) Mass Spectrometry: Method A Retention time Tr (min) = 0.84 [M + H] +: m / z 385 Stage d: 2.2 Dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one OmO / A mixture of 1 g of 7-chloro-2,2- dimethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one and 10 mL of morpholine is heated at 120 ° C for 1 hour. After cooling, the reaction mixture is concentrated under reduced pressure. The residue obtained is purified by chromatography on silica (eluent: CH 2 Cl 2 / MeOH 97/03) to give 650 mg of 2,2-dimethyl-7-morpholin-4-yl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one having the following characteristics: Mass spectrometry: method A [M + H] +: m / z 25115 Stage c: 7-Chloro-2,2-dimethyl-2 3-Dihydro-1H-imidazo [1,2-a] pyrimidin-5-one O <Ny 1

4.5 g of 7-hydroxy-2,2-dimethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one and 35 ml of sodium oxychloride are introduced into a flask. phosphorus. The resulting mixture is then heated at 120 ° C for three hours. After cooling, the reaction mixture is concentrated to dryness under reduced pressure. On the residue obtained, ice is added and then concentrated sodium hydroxide is added until a pH close to 5-6 is obtained. The solid formed is filtered to give 1 g of 7-chloro-2,2-dimethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one, in the form of a brown solid, whose characteristics are as follows: Mass spectrometry: method B [M + H] +: m / z 200; [MH] -: m / z 198 Step b: 7-hydroxy-2,2-dimethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one The procedure is as described. in Step g of Example 1, starting from 5 g of 4,4-dimethyl-imidazolidin-2-ylideneamine hydrobromide, 4 ml of diethyl malonate and 2.8 g of sodium methoxide. 4.5 g of 7-hydroxy-2,2-dimethyl-2,3-dihydro-1H-imidazo [1,2-a] pyrimidin-5-one are thus obtained in the form of a white solid. Stage a: 4,4-Dimethyl-imidazolidin-2-ylideneamine hydrobromide ΔH HNNH H3C CH3

The procedure described in Step f of Example 1 is carried out starting from 21 g of 1,2-diamino-2-methylpropane and 25.3 g of cyanogen bromide. 46 g of 4,4-dimethylimidazolidin-2-ylideneamine hydrobromide are thus obtained in the form of a white solid, the characteristics of which are as follows:

Mass Spectrometry: Method B

[M + H] +: m / z 114 Example 18: Pharmaceutical composition Tablets having the following formula were prepared:

Product of Example 1 0.2 g

Excipient for a tablet finished at 1 g

(details of the excipient: lactose, talc, starch, magnesium stearate).

Example 1 is taken as an example of a pharmaceutical preparation, which preparation can be carried out if desired with other products as examples in the present application.

Pharmacological part:

Experimental protocols

In vitro experimental procedures

The inhibitory activity of the molecules on AKT phosphorylation is measured either by western blotting by the technique described below, or by the MSD Multi-spot Biomarker detection technique of Meso Scale Discovery also described below. It has been demonstrated on a set of molecules that the two techniques give compatible results. BrH Study of the expression of pAKT in human PC3 prostate carcinoma cells measured by western blotting (Test A): This test is based on the measurement of the expression of the phosphorylated AKT protein on serine 473. AKT (pAKT) is measured by western blotting in the PC3 human prostate carcinoma line (ATCC CRL-1435), using an antibody specifically recognizing pAKT-S473. On day 1, the PC3 cells are seeded in 6-well plates (TPP, # 92006) at a concentration of 0.8 × 10 6 cells / well in 1800 μl of DMEM medium (DMEM Gibco # 11960-044) containing 10% fetal calf serum. (Gibco SVF, # 10500-056) and 1% Glutamine (Gibco L-Glu # 25030-024), and incubated at 37 ° C, 5% CO2, overnight. On day 2, the cells are incubated in the presence or absence of test products for 1 to 2 hours at 37 ° C. in the presence of 5% CO 2. The molecules diluted in dimethylsulfoxide (DMSO Sigma # D2650) are added from a stock solution concentrated 10 times, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 μM, or at increasing concentrations in a range that may range from less than 1 nM to 10 μM.

After this incubation, the cells are lysed for the preparation of the proteins. After aspiration of the culture medium, the cells are rinsed with 1 ml of PBS (Gibco DPBS, # 14190-094), recovered by scraping into 200 μl of complete HNTG buffer and transfer to 96-well plate (Greiner # 651201), and lysed for 1H on ice. The HNTG buffer is composed of the following mixture: 50 mM Hepes, 150 mM NaCl, 1% Triton, 10% Glycerol, with extemporaneous addition of a Protease Inhibitor Cocktail Mini tablet (Roche 1836153) and a Phosphatase Inhibitor Cocktail pellet (Roche104906837001) for 10ml of buffer. The lysate is centrifuged for 10 min at 6000 rpm. 155 μl of supernatant are recovered. 150 μl were incubated for denaturation for 5min at 95 ° C in the presence of 4X NuPAGE LDS Sample Buffer buffer diluted 4-fold (Ref InVitrogen NP0007) and NuPAGE 10X Sample Reducing Agent diluted 10-fold (Ref InVitrogen NP0009). These samples are then frozen at -20 ° C. 5 μl are assayed by the microBCA technique according to the MicroBCA Protein Assay Kit (Pierce # 23235). For the separation of the proteins, 20 μg of proteins are deposited on NU-PAGE gel 4-12% Bis Tris Gel 12 wells (Ref InVitrogen NP0322BOX) and the migration is carried out for 1 h 30 in migration buffer NU-PAGE MOPS SDS Running Buffer 20X diluted 20 times (Ref InVitrogen NP0001), at 150 volts. The gel is then transferred to an Invitrolon PVDF membrane (Invitrogen # LC2007) previously permeabilized for a few seconds in ethanol (Ethanol Fischer Scientific # E / 0600DF / 15). The transfer is carried out in a Biorad vat at 30 volts overnight or at 60 volts for 3 hours, in the presence of transfer buffer NUPAGE Transfer Buffer 20X diluted 20 times (Ref InVitrogen NP0006). The membrane is then saturated in saturation solution composed of TBS (Tris Buffer Saline 10x, Sigma # T5912 Sigma, diluted 10 times), Tween 20 0.1% (# P5927 Sigma) and BSA 3% (Bovine Albumin Serum Fraction V, Sigma # A4503) during 6 hours after a transfer of a duration of one night or during lh after a transfer of a duration of 3h. The primary antibodies are diluted 1/1000 for the anti-phospho antibody AKT-Ser473 (193H2, rabbit monoclonal, cat # 4058 from Cell Signaling Technology) Abcam), in saturation solution composed of PBS, Tween 20 0.1. %, BSA 3%, then stirred overnight at 4 ° C. Two rinses of 5 minutes in washing solution composed of TBS, 0.1% Tween 20 are carried out before the hybridization of the secondary antibodies. The secondary antibodies are diluted 1 / 10,000th for Rabbit anti-mouse IgG HRP antibody (W402 Promega) and 1 / 10,000th for Goat anti-Rabbit IgG HRP antibody (W401 Promega) in saturation solution and then put under control. stirring for 1h at room temperature. Two rinses of 30 minutes in washing solution are carried out then a rinsing of 5 minutes with H2O is carried out to eliminate the remaining Tween 20.

The visualization solution is volume-to-volume prepared according to the data sheet of the Western Lightning Chemiluminescence Reagent Plus (Western Lightning Chemiluminescence Reagent Plus Perkin Elmer # NEL104). The membrane is placed for 1 min in the developer solution, drained, inserted between two transparencies and placed in the meter for reading the luminescence and quantizing the signal. Luminescence is read with FujiFilm (Ray Test). The FUJI device measures the total luminescence signal obtained (AU) for each selected band. Then it subtracts the background noise (BG) proportional to the size of the selected band (Area), background noise calculated from a specific background noise band, in order to obtain the specific signal (AU-BG ) for each band. The band obtained in the absence of product and in the presence of 0.1% DMSO is considered as the 100% signal. The software calculates the% specific activity (Ratio) obtained for each selected band based on this 100% signal. The percent inhibition calculation is done for each concentration according to the formula (100% - Ratio). 2 independent experiments make it possible to calculate the average of the percentages of inhibition obtained at a given concentration for the products tested only at a concentration.

Where appropriate, the activity of the products is translated into approximate IC50, obtained from a dose-response curve of different concentrations tested and representing the dose giving 50% specific inhibition (absolute IC 50). 2 independent experiments allow to calculate the average of C150s.

Study of the expression of pAKT in PC3 human prostate carcinoma cells measured by the MSD Multi-spot Biomarker Detection technique of Meso Scale Discovery (Test B): This test is based on the measurement of AKT protein expression phosphorylated on serine 473 (P-AKT-S473), in the human prostate carcinoma cell line PC3, by the sandwich-based immunoassay technique using MSD Multi-spot Biomarker Detection Kit from Meso Scale Discovery: phosphor kits Akt (Ser473) whole cell lysate (# K151 CAD) or phospho-Akt (Ser473) / Total Akt whole cell lysate (# K151O0D). The primary antibody specific for P-AKT-S473 (Kit # K151 CAD) is coated on one electrode in each well of the MSD kit 96-well plates: after addition of a protein lysate in each well, the signal is exposed. by the addition of a labeled secondary detection antibody with an electrochemiluminescent compound. The procedure followed is that described in the kit.

On day 1, the PC3 cells are seeded in 96-well plates (TPP, # 92096) at a concentration of 35,000 cells / well in 200 μl of DMEM medium (DMEM Gibco # 11960-044) containing 10% fetal calf serum ( SVF Gibco, # 10500-056) and 1% Glutamine (L-Glu Gibco # 25030-024), and incubated at 37 ° C, 5% CO2, overnight.

On day 2, the cells are incubated in the presence or absence of test products for 1 to 2 hours at 37 ° C. in the presence of 5% CO 2. The molecules diluted in dimethylsulfoxide (DMSO Sigma # D2650), are added from a stock solution concentrated 20 times, the final percentage of DMSO being 0.1%. The molecules are tested either at a single concentration of less than or equal to 10 μM, or at increasing concentrations in a range that may range from less than 1 nM to 10 μM. After this incubation, the cells are lysed for the preparation of the proteins. For this, after aspiration of the culture medium, 50 μl of Tris Lysis Buffer complete lysis buffer of the MSD kit containing the protease inhibitor and phosphatase solutions are added to the wells and the cells are lysed for 1 h at 4 ° C. with shaking. . At this stage the plates containing the lysates can be frozen at -20 ° C or -80 ° C. The wells of the 96-well plates of the MSD kit are saturated for 1 hour at room temperature with the blocking solution of the MSD kit. Four washes are performed with 150 μl of Tris Wash Buffer from the MSD kit. The lysates prepared previously are transferred to the multispot 96 well plates of the MSD kit and incubated for 1 hour at room temperature, with stirring. Four washes are performed with 150 μl Tris Wash Buffer Wash Solution from the MSD kit. 25 μl of the MSD sulfo-tag detection antibody solution are added to the wells and incubated for 1 h at room temperature, with stirring. Four washes are performed with 150 μl Tris Wash Buffer Wash Solution from the MSD kit. 150p1 Read Buffer revelation buffer from the MSD kit is added to the wells and the plates are read immediately on the S12400 Meso Scale Discovery Instrument. The device measures a signal for each well. Cell-free wells containing the lysis buffer are used to determine the background noise that will be subtracted from all measurements (min). Wells containing cells in the absence of product and in the presence of 0.1% DMSO are considered the 100% signal (max). The percentage inhibition is calculated for each concentration of product tested according to the following formula: (1- ((swarmin) / (max-min))) xl 00. The activity of the product is translated to IC 50, obtained at from a dose-response curve of different concentrations tested and representing the dose giving 50% specific inhibition (IC50 absolute). 2 independent experiments allow to calculate the average of C15os. The results obtained for the exemplary products in the experimental part are given in the table of pharmacological results below: Table of pharmacological results: Example Test A * Test B * Example 1 +++ Example 2 +++ Example 3 ++ Example 4 +++ Example 5 +++ Example 6 ++ Example 7 Example 8 +++ Example 9 Example 10 +++ Example 11 Example 12 +++ Example 13 Example 14 +++ Example 15 +++ Example 16 +++ Example 17 * For tests A and B the IC50 (nM) are distributed as follows: +> 5pM 500nM <++ <5pM +++ <500nM 10

Claims (15)

CLAIMS1) Products of formula (I): R3 (R2 N-R1 wherein: R1 represents a -L-aryl or -L-heteroaryl radical, such that L represents: either a linear or branched alkyl radical containing from 1 to 6 atoms of carbon and optionally substituted by a hydroxyl radical, either a CO group or a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur, the aryl and heteroaryl radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and hydroxyl, CN, nitro, -000H, -COOalk, -NRxRy, -CONRxRy, -NRxCORy radicals, -NRxCO2Rz, -CORy, alkoxy, phenoxy, alkylthio, alkyl, cycloalkyl and heterocycloalkyl, the latter radicals alkoxy, phenoxy, alkylthio, alkyl and heterocycloalkyl, being themselves optionally substituted by one or more identical or different radicals chosen; is among halogen atoms and NRvRw; Heterocycloalkyl and heteroaryl radicals additionally capable of containing an oxo radical; R2 represents a hydrogen atom or an alkyl radical; R3 represents an alkyl radical optionally substituted with one or more halogen atoms; R4 represents a hydrogen atom or a halogen atom; NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and NRvRw radicals; and heterocycloalkyl; either Rx and Ry form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted; NRvRw being such that Rv represents a hydrogen atom or an alkyl radical and Rw represents a hydrogen atom, a cycloalkyl radical or an alkyl radical optionally substituted with one or more identical or different radicals chosen from hydroxyl, alkoxy and heterocycloalkyl radicals; ; either Rv and Rw form, with the nitrogen atom to which they are bonded, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, NH and N-alkyl, this cyclic radical being optionally substituted; the cyclic radicals that can be formed by Rx and Ry or Rv and Rw respectively with the nitrogen atom to which they are attached, being optionally substituted by one or more identical or different radicals chosen from halogen atoms, alkyl radicals, hydroxyl radicals, oxo, alkoxy, NH2; NHalk and N (alk) 2; Rz represents the values of Ry with the exception of hydrogen; Rx, Ry and Rz in the radicals -NRxCORy, -CORy and NRxCO2Rz being selected from the meanings indicated above for Rx, Ry, and Rz; all the above alkyl (alk), alkoxy and alkylthio radicals being linear or branched and containing from 1 to 6 carbon atoms, said products of formula (I) being in all the possible isomeric forms racemic, enantiomers and diastereoisomers, as well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I). 2) Products of formula (I) as defined in claim 1 wherein: R1 represents a -L-phenyl or -L-heteroaryl radical, such that L represents: either a linear or branched alkyl radical containing from 1 to 6 atoms of carbon and optionally substituted with a hydroxyl radical, either a CO group or a group L'-X where L 'represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms and X an oxygen or sulfur; the phenyl and heteroaryl radicals being optionally substituted with one or more identical or different radicals chosen from halogen atoms and -NRxRy, alkoxy and alkyl radicals; these latter alkoxy and alkyl radicals themselves being optionally substituted by one or more radicals chosen from halogen atoms; R2 represents an alkyl radical; R3 represents an alkyl radical optionally substituted with one or more halogen atoms; R4 represents a hydrogen atom or a fluorine atom; NRxRy being such that Rx represents a hydrogen atom or an alkyl radical and Ry represents a hydrogen atom or an alkyl radical; either R 1 and R 2 together with the nitrogen atom to which they are attached form a morpholino radical; all the above alkyl (alk) or alkoxy radicals being linear or branched and containing from 1 to 6 carbon atoms, said products of formula (I) being in all isomeric possible racemic, enantiomeric and diastereoisomeric forms, as well as addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I). 3) Products of formula (I) as defined in any one of claims 1 or 2, having the following formulas: - (2S) -1- [2- (4-methoxyphenyl) ethyl] -2-methyl-7 - (Morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one 10 - 1- [2- (4-methoxyphenyl) ethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1-benzyl -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl (7-morpholin-4-yl) -1- (2-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) 2-methyl-7- (morpholin-4-yl) -1- (3-phenylpropyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) - one - (2S) -2-methyl-7- (morpholin-4-yl) -1- (2-phenoxyethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 ( 1 H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1- [2- (phenylsulfanyl) ethyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1, 2 -a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2R) -2-phenylpropyl] -2- (trifluoromethyl) -2 3-Dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) -2-phenylpropyl] 2- (Trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -1 - [(2S) -2-hydroxy-2-phenylethyl] -2 methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one5 - (2S) -1 - [( 2R) -2-hydroxy-2-phenylethyl] -2-methyl-7- (morpholin-4-yl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) ) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(2S) -1-phenylpropan-2-yl] -2- (trifluoromethyl) -2,3-d ihyd roimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1 - [(1S) -1-phenylpropyl] 2- (Trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1- [(1 R) -1-phenylpropyl] -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- ( morpholin-4-yl ) -1- {2- [4- (Morpholin-4-yl) phenyl] ethyl} -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1H) -one - (2S) -2-methyl-7- (morpholin-4-yl) -1- (1-phenylethyl) -2- (trifluoromethyl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 (1S) H) -one - 1- [2- (4-methoxyphenyl) ethyl] -2,2-dimethyl-7- (morpholin-4-yl) -2,3-dihydroimidazo [1,2-a] pyrimidin-5 ( 1 H) -one as well as the addition salts with the mineral and organic acids or with the inorganic and organic bases of said products of formula (I). 4) Process for the preparation of the products of formula (I) as defined in any one of claims 1 to 3 according to scheme 1 as defined below. Embedded image wherein R 1, R 2, R 3 and R 4 have the meanings indicated in any one of claims 1 or 2, wherein R 1, R 2, R 3 and R 4 have the meanings indicated in any one of claims 1 or 2; And wherein R is alkyl. X represents a chlorine, bromine or iodine atom or a sulfonyloxy group such as trifluoromethylsulfonyloxy. 5) As medicaments, the products of formula (I) as defined in any one of claims 1 to 3, and the addition salts with inorganic and organic acids or with inorganic and organic bases pharmaceutically acceptable said products of formula (I). 6) As medicaments, the products of formula (I) as defined in claim 3, as well as the addition salts with inorganic and organic acids or with the pharmaceutically acceptable inorganic and organic bases of said products of formula (I ). 7) Pharmaceutical compositions containing as active ingredient at least one of the products of formula (I) as defined in any one of claims 1 to 3, or a pharmaceutically acceptable salt of this product or a prodrug of this product and a pharmaceutically acceptable carrier. 8) Use of a product of formula (I) as defined in any one of claims 1 to 3 for the preparation of a medicament for the treatment of cancers. 9) Use according to claim 8 for the treatment of solid or liquid tumors. 10) Use according to claim 8 and 9 for the treatment of cancers resistant to cytotoxic agents. 11) Use according to one or more of claims 8 to 10 for the treatment of primary tumors and / or metastases especially in gastric, hepatic, renal, ovarian, colon, prostate, endometrial cancers, lung cancer (NSCLC and SCLC), glioblastoma, thyroid, bladder, breast, melanoma, lymphoid or myeloid hematopoietic tumors, sarcomas, brain, larynx, lymphatic system, cancers of the bones and pancreas, in hamartomas. 12) Use of the products of formula (I) as defined in claims 1 to 3 for the preparation of medicaments for the chemotherapy of cancers. 13) Use of the products of formula (I) as defined in claims 1 to 3, for the preparation of medicaments for cancer chemotherapy alone or in combination. 14) Products of formula (I) as defined in any one of claims 1 to 3 as inhibitors of phosphorylation of AKT (PKB) 15) As novel industrial products, the synthetic intermediates of formulas D, E, F and J as defined in claim 4 above and recalled below: JDE 25 in which R1, R2, R3 and R4 have the definitions given in any one of claims 1 to 2.